SMILES,Conditions,Name,NCT_Number,Phases,Status,Gender,Age,Funded Bys,Study Designs,Locations,Patent_id,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,CPC_code_0,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,PCT_code_2,CPC_code_1,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,PROSTATIC NEOPLASMS,_LEUPROLIDE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",5728396.0,A61K38/09,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CC(=O)[O-],PROSTATIC NEOPLASMS,_ACETATE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,PROSTATIC NEOPLASMS,_LEUPROLIDE_ACETATE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",4851211,A61K9/008,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PROSTATIC NEOPLASMS,_PREDNISONE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,PROSTATIC NEOPLASMS,_ABIRATERONE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",5604213,C07J41/0005,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,PROSTATIC NEOPLASMS,_ABIRATERONE_ACETATE,NCT03007732,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Francisco, San Francisco, California, United States",5604213,C07J41/0005,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,28.6494589211277,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,URINARY TRACT INFECTIONS,_ESTRADIOL,NCT04301934,Not Applicable,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mayo Clinic in Arizona, Phoenix, Arizona, United States",5223261,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,URINARY TRACT INFECTIONS,_ESTROGEN,NCT04301934,Not Applicable,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mayo Clinic in Arizona, Phoenix, Arizona, United States",,,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,OVARIAN CANCER,_EXEMESTANE,NCT04460807,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AO SS Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy|Ospedale Oncologico IRCCS Bari, Bari, BA, Italy|Ospedale degli Infermi, Biella, BI, Italy|AULSS 1 Dolomiti - Ospedale ""Santa Maria del Prato"", Feltre, BL, Italy|Azienda Ospedaliero Universitaria Policlinico S.Orsola-Malpighi, Bologna, BO, Italy|ASST degli Spedali Civili di Brescia, Brescia, BS, Italy|Fondazione Poliambulanza, Brescia, BS, Italy|Ospedale di Manerbio, Manerbio, BS, Italy|AOU Cagliari, Policlinico Universitario, Cagliari, CA, Italy|Ospedale Policlinico ""SS. Annunziata"", Chieti, CH, Italy|Azienda Sanitaria Locale CN2, Alba, CN, Italy|Azienda Ospedaliera S.Croce e Carle, Cuneo, CN, Italy|Ospedale di Mondovì CN1, Mondovì, CN, Italy|Ospedale Sant Anna di Como, Como, CO, Italy|ARNAS Garibaldi, Catania, CT, Italy|Azienda Ospedaliera per l'emergenza Cannizzaro, Catania, CT, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy|Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy|ASL 3 Ospedale Villa Scassi, Genova, GE, Italy|IRCCS AOU San Martino - IST, Genova, GE, Italy|ASST Lecco - Ospedale ""A. Manzoni"", Lecco, LC, Italy|Ospedale ""Vito Fazzi"", Lecce, LE, Italy|UOS Oncologia Ginecologica, Ospedale S. Gerardo, Monza, MB, Italy|Presidio Ospedaliero Unico Av3, Macerata, MC, Italy|Istituto Europeo di Oncologia (IEO), Milano, MI, Italy|AOU Policlinico di Modena, Modena, MO, Italy|A.R.N.A.S. Ospedali Civico Di Cristina Benfratelli, Palermo, PA, Italy|Ospedale ""Guglielmo da Saliceto"", Piacenza, PC, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, PI, Italy|CRO Centro di Riferimento Oncologico, Aviano, PN, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy|Azienda Ospedaliera Regionale San Carlo, Potenza, PZ, Italy|Ospedale ""degli Infermi"", Faenza, RA, Italy|Ospedale ""Umberto I"", Lugo, RA, Italy|Ospedale Santa Maria delle Croci, Ravenna, RA, Italy|Azienda Ospedaliera Arcispedale Santa Maria Nuova, Reggio Emilia, RE, Italy|Policlinico Umberto I, Università di Roma ""La Sapienza"", Roma, RM, Italy|Policlinico Universitario Fondazione Agostino Gemelli, Roma, RM, Italy|ASST Valtellina e Alto Lario, Sondrio, SO, Italy|Azienda Ospedaliero Universitaria di Sassari, Sassari, SS, Italy|Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, TO, Italy|AO Ordine Mauriziano, Torino, TO, Italy|Azienda Ospedaliero-Universitaria Città della Salute e della Scienza - Ospedale Ostetrico Ginecologico Sant'Anna, Torino, TO, Italy|Presidio Ospedaliero S. Andrea, Vercelli, VC, Italy|Medical Oncology Division, Ente Ospedaliero Ospedali Galliera, Genova, Italy|Istituto Nazionale Tumori - IRCCS ""Fondazione G.Pascale"", Napoli, Italy|Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy",4808616,C07J1/0011,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,OVARIAN CANCER,_LETROZOLE,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",4978672,C07D213/57,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,OVARIAN CANCER,_METFORMIN,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",6288095.0,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)Oc1ccccc1C(=O)O,OVARIAN CANCER,_ASPIRIN,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",6015577,6,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,OVARIAN CANCER,_OLAPARIB,NCT03378297,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Helse Bergen HF, Haukeland University Hospital, Bergen, Norway|Helse Stavanger HF, Stavanger University Hospital, Stavanger, Norway",7151102,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,PCOS,_FLUTAMIDE,NCT00930228,Phase 1,Recruiting,Female,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","University of Virginia, Charlottesville, Virginia, United States",3995060,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,26.6453109920121,2145.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,276.2118,74.92,3.0,1.0,1.0,23.2,63.42,4.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,NEOPLASMS,_DOCETAXEL,NCT03693612,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",4814470,C07D305/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,NEOPLASMS,_PACLITAXEL,NCT03693612,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,PROSTATE CANCER,_NIRAPARIB,NCT04194554,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States",8859562,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,PROSTATIC NEOPLASMS,_ENZALUTAMIDE,NCT03834519,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Joseph Heritage Healthcare ( Site 0069), Fullerton, California, United States|UCLA Hematology & Oncology ( Site 0081), Santa Monica, California, United States|Sibley Memorial Hospital ( Site 0096), Washington, District of Columbia, United States|Georgia Cancer Center at Augusta University ( Site 0026), Augusta, Georgia, United States|Quincy Medical Group ( Site 0021), Quincy, Illinois, United States|Tulane Cancer Center ( Site 0066), New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0005), Baltimore, Maryland, United States|Chesapeake Urology Research Associates ( Site 0076), Towson, Maryland, United States|Beth Israel Deaconess Medical Ctr. ( Site 0093), Boston, Massachusetts, United States|Dana Farber Cancer Institute ( Site 0033), Boston, Massachusetts, United States|UMass Memorial Medical Center ( Site 0053), Worcester, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute ( Site 0077), Detroit, Michigan, United States|Henry Ford Health System ( Site 0039), Detroit, Michigan, United States|St. Vincent Frontier Cancer Center ( Site 0016), Billings, Montana, United States|Nebraska Cancer Specialists ( Site 0034), Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada ( Site 0092), Las Vegas, Nevada, United States|University of New Mexico Cancer Center ( Site 0048), Albuquerque, New Mexico, United States|Memorial Medical Center ( Site 0095), Las Cruces, New Mexico, United States|Associated Medical Professionals of NY ( Site 0060), Syracuse, New York, United States|Duke Cancer Center Cary ( Site 0010), Cary, North Carolina, United States|The Urology Group- Cincinnati ( Site 0094), Cincinnati, Ohio, United States|University Hospitals of Cleveland Seidman Cancer Center ( Site 0036), Cleveland, Ohio, United States|Carolina Urologic Research Center ( Site 0070), Myrtle Beach, South Carolina, United States|Huntsman Cancer Institute ( Site 0002), Salt Lake City, Utah, United States|Virginia Cancer Institute ( Site 0052), Richmond, Virginia, United States|Blue Ridge Cancer Care ( Site 0086), Roanoke, Virginia, United States|Seattle Cancer Care Alliance ( Site 0079), Seattle, Washington, United States|Froedtert and Medical College of Wisconsin ( Site 0045), Milwaukee, Wisconsin, United States|Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013), Berazategui, Buenos Aires, Argentina|Centro de Diagnostico Urologico ( Site 1008), Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina|Hospital Britanico de Buenos Aires ( Site 1006), Caba, Ciudad Autonoma De Buenos Aires, Argentina|Instituto Medico Alexander Fleming ( Site 1010), Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina|Sanatorio Parque ( Site 1002), Rosario, Santa Fe, Argentina|Hospital Aleman ( Site 1004), Buenos Aires, Argentina|CEMAIC ( Site 1014), Cordoba, Argentina|St. Vincent's Hospital ( Site 0158), Darlinghurst, New South Wales, Australia|Macquarie University ( Site 0151), Macquarie University, New South Wales, Australia|Port Macquarie Base Hospital ( Site 0153), Port Macquarie, New South Wales, Australia|Calvary Mater Newcastle ( Site 0148), Waratah, New South Wales, Australia|Southern Medical Day Care Centre ( Site 0160), Wollongong, New South Wales, Australia|Royal Brisbane and Women s Hospital ( Site 0155), Herston, Queensland, Australia|John Flynn Hospital & Medical Centre ( Site 0164), Tugun, Queensland, Australia|Box Hill Hospital ( Site 0146), Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre ( Site 0152), Melbourne, Victoria, Australia|Fiona Stanley Hospital ( Site 0162), Murdoch, Western Australia, Australia|Ordensklinikum Linz GmbH Elisabethinen ( Site 0373), Linz, Oberosterreich, Austria|Medizinische Universitat Graz ( Site 0374), Graz, Steiermark, Austria|SCRI-CCCIT GesmbH ( Site 0371), Salzburg, Austria|Medizinische Universitaet Wien ( Site 0375), Wien, Austria|Hospital de Caridade de Ijui ( Site 1038), Ijui, Rio Grande Do Sul, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021), Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035), Itajai, Santa Catarina, Brazil|Hospital de Base de Sao Jose de Rio Preto ( Site 1022), Sao Jose do Rio Preto, Sao Paulo, Brazil|A.C. Camargo Cancer Center ( Site 1026), Sao Paulo, Brazil|Cross Cancer Institute ( Site 0110), Edmonton, Alberta, Canada|BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0113), Kelowna, British Columbia, Canada|BC Cancer-Vancouver Center ( Site 0112), Vancouver, British Columbia, Canada|Nova Scotia Health Authority QEII-HSC ( Site 0114), Halifax, Nova Scotia, Canada|Juravinski Cancer Centre ( Site 0116), Hamilton, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada|CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102), Rimouski, Quebec, Canada|CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105), Sherbrooke, Quebec, Canada|CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103), Quebec, Canada|Private practice ( Site 1048), Temuco, Araucania, Chile|Sociedad de Investigaciones Medicas Limitadas ( Site 1041), Temuco, Araucania, Chile|Fundacion Arturo Lopez Perez ( Site 1049), Santiago, Region Metropolitana De Santiago, Chile|Bradford Hill Centro de Investigaciones Clinicas ( Site 1044), Santiago, Region Metropolitana De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 1047), Santiago, Región Metropolitana De Santiago, Chile|C.H. de Saint Quentin ( Site 0481), Saint Quentin, Aisne, France|Centre Leon Berard ( Site 0422), Lyon, Auvergne, France|Clinique Sainte Anne ( Site 0431), Strasbourg, Bas-Rhin, France|Institut Paoli Calmettes ( Site 0419), Marseille, Bouches-du-Rhone, France|CHU Jean Minjoz ( Site 0423), Besancon, Doubs, France|CHU de Brest -Site Hopital Morvan ( Site 0441), Brest, Finistere, France|Institut Bergonie ( Site 0421), Bordeaux, Gironde, France|Institut Claudius Regaud IUCT Oncopole ( Site 0418), Toulouse, Haute-Garonne, France|Hopital Foch ( Site 0428), Suresnes, Hauts-de-Seine, France|Institut Regional du Cancer de Montpellier - ICM ( Site 0443), Montpellier, Herault, France|Institut De Cancerologie De L Ouest ( Site 0448), Saint Herblain, Loire-Atlantique, France|Centre Hospitalier Regional du Orleans ( Site 0430), Orleans, Loiret, France|Centre D Oncologie de Gentilly ( Site 0432), Nancy, Meurthe-et-Moselle, France|Institut Sainte Catherine ( Site 0447), Avignon, Provence-Alpes-Cote-d'Azur, France|Centre Jean Perrin ( Site 0434), Clermont-Ferrand, Puy-de-Dome, France|C.H.U. Lyon Sud ( Site 0436), Pierre Benite, Rhone, France|CHU Amiens Picardie Site Sud Amiens ( Site 0438), Amiens, Somme, France|Institut Gustave Roussy ( Site 0416), Villejuif, Val-de-Marne, France|Institut Mutualiste Montsouris ( Site 0446), Paris, France|Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304), Freiburg, Baden-Wurttemberg, Germany|Universitaetsklinikum in Mannheim ( Site 0314), Mannheim, Baden-Wurttemberg, Germany|Studienpraxis Urologie ( Site 0309), Nuertingen, Baden-Wurttemberg, Germany|Universitaetsklinik fuer Urologie ( Site 0307), Tuebingen, Baden-Wurttemberg, Germany|Universitaetsklinikum Erlangen ( Site 0303), Erlangen, Bayern, Germany|Klinikum Rechts der Isar ( Site 0300), Muenchen, Bayern, Germany|Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318), Nuernberg, Bayern, Germany|Universitaetsklinikum Duesseldorf ( Site 0306), Duesseldorf, Nordrhein-Westfalen, Germany|Krankenhaus der Barmherzigen Brueder Trier ( Site 0310), Trier, Rheinland-Pfalz, Germany|Universitaetsklinikum Jena ( Site 0305), Jena, Thuringen, Germany|Charite Universitaetsmedizin Berlin ( Site 0301), Berlin, Germany|Tallaght University Hospital ( Site 0730), Dublin, Ireland|Mid Western Cancer Centre ( Site 0728), Limerick, Ireland|Meir Medical Center ( Site 0544), Kfar Saba, Central, Israel|Assaf Harofe ( Site 0547), Be'er- Ya'akov, HaMerkaz, Israel|Rabin Medical Center ( Site 0545), Petach-Tikwa, HaMerkaz, Israel|Ha Emek Medical Center ( Site 0548), Afula, HaTsafon, Israel|Soroka Medical Center ( Site 0549), Beer Sheva, Southern, Israel|Chaim Sheba Medical Center ( Site 0541), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 0542), Tel-Aviv, Tell Abib, Israel|Rambam Medical Center ( Site 0543), Haifa, Israel|Hadassah Ein Kerem Medical Center ( Site 0546), Jerusalem, Israel|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0462), Meldola, Forli-Cesena, Italy|Istituto Clinico Humanitas Research Hospital ( Site 0452), Rozzano, Milano, Italy|Medical Oncology Ospedale San Donato ( Site 0461), Arezzo, Italy|Policlinico S.Orsola-Malpighi ( Site 0453), Bologna, Italy|Azienda Ospedaliera Cannizzaro ( Site 0458), Catania, Italy|Azienda Ospedaliera San Camillo Forlanini ( Site 0455), Roma, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0463), Roma, Italy|Azienda Ospedaliera Santa Maria Terni ( Site 0456), Terni, Italy|Presidio Ospedaliero Santa Chiara ( Site 0451), Trento, Italy|Fujita Health University Hospital ( Site 0724), Toyoake, Aichi, Japan|National Cancer Center Hospital East ( Site 0702), Kashiwa, Chiba, Japan|Toho University Sakura Medical Center ( Site 0703), Sakura, Chiba, Japan|National Hospital Organization Shikoku Cancer Center ( Site 0716), Matsuyama, Ehime, Japan|Kobe City Medical Center General Hospital ( Site 0726), Kobe, Hyogo, Japan|Kanazawa University Hospital ( Site 0701), Kanazawa, Ishikawa, Japan|Kitasato University Hospital ( Site 0705), Sagamihara, Kanagawa, Japan|Yokohama City University Medical Center ( Site 0706), Yokohama, Kanagawa, Japan|Nara Medical University Hospital ( Site 0715), Kashihara, Nara, Japan|Kindai University Hospital ( Site 0714), Osakasayama, Osaka, Japan|Osaka University Hospital ( Site 0713), Suita, Osaka, Japan|Saitama Medical University International Medical Center ( Site 0708), Hidaka, Saitama, Japan|Dokkyo Medical University Saitama Medical Center ( Site 0707), Koshigaya, Saitama, Japan|Fuji City General Hospital ( Site 0725), Fuji, Shizuoka, Japan|Hamamatsu University Hospital ( Site 0720), Hamamatsu, Shizuoka, Japan|Yamaguchi University Hospital ( Site 0717), Ube, Yamaguchi, Japan|Chiba Cancer Center ( Site 0704), Chiba, Japan|Kyushu University Hospital ( Site 0718), Fukuoka, Japan|University of Miyazaki Hospital ( Site 0721), Miyazaki, Japan|Nagano Municipal Hospital ( Site 0723), Nagano, Japan|Nagasaki University Hospital ( Site 0719), Nagasaki, Japan|Osaka International Cancer Institute ( Site 0722), Osaka, Japan|Toranomon Hospital ( Site 0711), Tokyo, Japan|Nippon Medical School Hospital ( Site 0709), Tokyo, Japan|Keio University Hospital ( Site 0710), Tokyo, Japan|Chonnam National University Hwasun Hospital ( Site 0174), Hwasun Gun, Jeonranamdo, Korea, Republic of|National Cancer Center ( Site 0176), Goyang-si, Kyonggi-do, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0173), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Asan Medical Center ( Site 0171), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center ( Site 0172), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Medisch Centrum Leeuwarden ( Site 0477), Leeuwarden, Fryslan, Netherlands|Radboud University Medical Center ( Site 0470), Nijmegen, Gelderland, Netherlands|Antoni van Leeuwenhoek Ziekenhuis ( Site 0480), Amsterdam, Noord-Holland, Netherlands|Vrije Universiteit Medisch Centrum ( Site 0479), Amsterdam, Noord-Holland, Netherlands|Spaarne Ziekenhuis ( Site 0473), Hoofddorp, Noord-Holland, Netherlands|Ziekenhuisgroep Twente ( Site 0469), Almelo, Overijssel, Netherlands|Medisch Centrum Haaglanden ( Site 0471), Leidschendam, Zuid-Holland, Netherlands|Erasmus MC ( Site 0475), Rotterdam, Zuid-Holland, Netherlands|Franciscus Gasthuis en Vlietland ( Site 0489), Schiedam, Zuid-Holland, Netherlands|Auckland City Hospital ( Site 0193), Auckland, New Zealand|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565), Chelyabinsk, Chelyabinskaya Oblast', Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|Russian Scientific Center of Roentgenoradiology ( Site 0559), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 0562), Moscow, Moskva, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 0568), Omsk, Omskaya Oblast', Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576), Samara, Samarskaya Oblast', Russian Federation|SBHI Leningrad Regional Oncology Dispensary ( Site 0588), Saint Petersburg, Sankt-Peterburg, Russian Federation|Clinical Research Center of specialized types medical care-Oncology ( Site 0570), Saint Petersburg, Sankt-Peterburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567), Saint Petersburg, Sankt-Peterburg, Russian Federation|Tomsk National Scientific Medical Center of Russian Academy of Science ( Site 0579), Tomsk, Tomskaya Oblast', Russian Federation|Hospital del Mar ( Site 0333), Barcelona, Barcelona [Barcelona], Spain|Hospital General Universitari Vall d Hebron ( Site 0334), Barcelona, Barcelona [Barcelona], Spain|Hospital Clinic ( Site 0323), Barcelona, Barcelona [Barcelona], Spain|Instituto Catalan de Oncologia - ICO ( Site 0330), L Hospitalet De Llobregat, Barcelona [Barcelona], Spain|Hospital Parc Tauli ( Site 0335), Sabadell, Barcelona [Barcelona], Spain|Hospital Josep Trueta ( Site 0321), Girona, Girona [Gerona], Spain|Hospital Quiron Madrid ( Site 0325), Pozuelo de Alarcon, Madrid, Spain|Hospital San Pedro de Alcantara ( Site 0326), Caceres, Spain|Hospital Universitario Virgen de la Victoria ( Site 0337), Malaga, Spain|National Cheng Kung University Hospital ( Site 0134), Tainen, Tainan, Taiwan|China Medical University Hospital ( Site 0132), Taichung, Taiwan|Taichung Veterans General Hospital ( Site 0133), Taichung, Taiwan|National Taiwan University Hospital ( Site 0131), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 0135), Taipei, Taiwan|University Hospitals Bristol NHS Foundation Trust ( Site 0530), Bristol, Bristol, City Of, United Kingdom|Cambridge University Hospitals NHS Trust ( Site 0540), Cambridge, Cambridgeshire, United Kingdom|Musgrove Park Hospital ( Site 0537), Taunton, Somerset, United Kingdom|University of North Midlands NHS Foundation Trust ( Site 0527), Stoke-on-Trent, Staffordshire, United Kingdom|Mount Vernon Cancer Centre ( Site 0536), Northwood, United Kingdom|Royal Marsden Hospital ( Site 0526), Sutton, United Kingdom",7709517,C07D233/70,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PROSTATIC NEOPLASMS,_OLAPARIB,NCT03834519,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Joseph Heritage Healthcare ( Site 0069), Fullerton, California, United States|UCLA Hematology & Oncology ( Site 0081), Santa Monica, California, United States|Sibley Memorial Hospital ( Site 0096), Washington, District of Columbia, United States|Georgia Cancer Center at Augusta University ( Site 0026), Augusta, Georgia, United States|Quincy Medical Group ( Site 0021), Quincy, Illinois, United States|Tulane Cancer Center ( Site 0066), New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0005), Baltimore, Maryland, United States|Chesapeake Urology Research Associates ( Site 0076), Towson, Maryland, United States|Beth Israel Deaconess Medical Ctr. ( Site 0093), Boston, Massachusetts, United States|Dana Farber Cancer Institute ( Site 0033), Boston, Massachusetts, United States|UMass Memorial Medical Center ( Site 0053), Worcester, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute ( Site 0077), Detroit, Michigan, United States|Henry Ford Health System ( Site 0039), Detroit, Michigan, United States|St. Vincent Frontier Cancer Center ( Site 0016), Billings, Montana, United States|Nebraska Cancer Specialists ( Site 0034), Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada ( Site 0092), Las Vegas, Nevada, United States|University of New Mexico Cancer Center ( Site 0048), Albuquerque, New Mexico, United States|Memorial Medical Center ( Site 0095), Las Cruces, New Mexico, United States|Associated Medical Professionals of NY ( Site 0060), Syracuse, New York, United States|Duke Cancer Center Cary ( Site 0010), Cary, North Carolina, United States|The Urology Group- Cincinnati ( Site 0094), Cincinnati, Ohio, United States|University Hospitals of Cleveland Seidman Cancer Center ( Site 0036), Cleveland, Ohio, United States|Carolina Urologic Research Center ( Site 0070), Myrtle Beach, South Carolina, United States|Huntsman Cancer Institute ( Site 0002), Salt Lake City, Utah, United States|Virginia Cancer Institute ( Site 0052), Richmond, Virginia, United States|Blue Ridge Cancer Care ( Site 0086), Roanoke, Virginia, United States|Seattle Cancer Care Alliance ( Site 0079), Seattle, Washington, United States|Froedtert and Medical College of Wisconsin ( Site 0045), Milwaukee, Wisconsin, United States|Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013), Berazategui, Buenos Aires, Argentina|Centro de Diagnostico Urologico ( Site 1008), Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina|Hospital Britanico de Buenos Aires ( Site 1006), Caba, Ciudad Autonoma De Buenos Aires, Argentina|Instituto Medico Alexander Fleming ( Site 1010), Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina|Sanatorio Parque ( Site 1002), Rosario, Santa Fe, Argentina|Hospital Aleman ( Site 1004), Buenos Aires, Argentina|CEMAIC ( Site 1014), Cordoba, Argentina|St. Vincent's Hospital ( Site 0158), Darlinghurst, New South Wales, Australia|Macquarie University ( Site 0151), Macquarie University, New South Wales, Australia|Port Macquarie Base Hospital ( Site 0153), Port Macquarie, New South Wales, Australia|Calvary Mater Newcastle ( Site 0148), Waratah, New South Wales, Australia|Southern Medical Day Care Centre ( Site 0160), Wollongong, New South Wales, Australia|Royal Brisbane and Women s Hospital ( Site 0155), Herston, Queensland, Australia|John Flynn Hospital & Medical Centre ( Site 0164), Tugun, Queensland, Australia|Box Hill Hospital ( Site 0146), Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre ( Site 0152), Melbourne, Victoria, Australia|Fiona Stanley Hospital ( Site 0162), Murdoch, Western Australia, Australia|Ordensklinikum Linz GmbH Elisabethinen ( Site 0373), Linz, Oberosterreich, Austria|Medizinische Universitat Graz ( Site 0374), Graz, Steiermark, Austria|SCRI-CCCIT GesmbH ( Site 0371), Salzburg, Austria|Medizinische Universitaet Wien ( Site 0375), Wien, Austria|Hospital de Caridade de Ijui ( Site 1038), Ijui, Rio Grande Do Sul, Brazil|Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021), Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035), Itajai, Santa Catarina, Brazil|Hospital de Base de Sao Jose de Rio Preto ( Site 1022), Sao Jose do Rio Preto, Sao Paulo, Brazil|A.C. Camargo Cancer Center ( Site 1026), Sao Paulo, Brazil|Cross Cancer Institute ( Site 0110), Edmonton, Alberta, Canada|BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0113), Kelowna, British Columbia, Canada|BC Cancer-Vancouver Center ( Site 0112), Vancouver, British Columbia, Canada|Nova Scotia Health Authority QEII-HSC ( Site 0114), Halifax, Nova Scotia, Canada|Juravinski Cancer Centre ( Site 0116), Hamilton, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0107), Toronto, Ontario, Canada|CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102), Rimouski, Quebec, Canada|CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105), Sherbrooke, Quebec, Canada|CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0103), Quebec, Canada|Private practice ( Site 1048), Temuco, Araucania, Chile|Sociedad de Investigaciones Medicas Limitadas ( Site 1041), Temuco, Araucania, Chile|Fundacion Arturo Lopez Perez ( Site 1049), Santiago, Region Metropolitana De Santiago, Chile|Bradford Hill Centro de Investigaciones Clinicas ( Site 1044), Santiago, Region Metropolitana De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 1047), Santiago, Región Metropolitana De Santiago, Chile|C.H. de Saint Quentin ( Site 0481), Saint Quentin, Aisne, France|Centre Leon Berard ( Site 0422), Lyon, Auvergne, France|Clinique Sainte Anne ( Site 0431), Strasbourg, Bas-Rhin, France|Institut Paoli Calmettes ( Site 0419), Marseille, Bouches-du-Rhone, France|CHU Jean Minjoz ( Site 0423), Besancon, Doubs, France|CHU de Brest -Site Hopital Morvan ( Site 0441), Brest, Finistere, France|Institut Bergonie ( Site 0421), Bordeaux, Gironde, France|Institut Claudius Regaud IUCT Oncopole ( Site 0418), Toulouse, Haute-Garonne, France|Hopital Foch ( Site 0428), Suresnes, Hauts-de-Seine, France|Institut Regional du Cancer de Montpellier - ICM ( Site 0443), Montpellier, Herault, France|Institut De Cancerologie De L Ouest ( Site 0448), Saint Herblain, Loire-Atlantique, France|Centre Hospitalier Regional du Orleans ( Site 0430), Orleans, Loiret, France|Centre D Oncologie de Gentilly ( Site 0432), Nancy, Meurthe-et-Moselle, France|Institut Sainte Catherine ( Site 0447), Avignon, Provence-Alpes-Cote-d'Azur, France|Centre Jean Perrin ( Site 0434), Clermont-Ferrand, Puy-de-Dome, France|C.H.U. Lyon Sud ( Site 0436), Pierre Benite, Rhone, France|CHU Amiens Picardie Site Sud Amiens ( Site 0438), Amiens, Somme, France|Institut Gustave Roussy ( Site 0416), Villejuif, Val-de-Marne, France|Institut Mutualiste Montsouris ( Site 0446), Paris, France|Universitaetsklinikum Freiburg - Medizinische Klinik ( Site 0304), Freiburg, Baden-Wurttemberg, Germany|Universitaetsklinikum in Mannheim ( Site 0314), Mannheim, Baden-Wurttemberg, Germany|Studienpraxis Urologie ( Site 0309), Nuertingen, Baden-Wurttemberg, Germany|Universitaetsklinik fuer Urologie ( Site 0307), Tuebingen, Baden-Wurttemberg, Germany|Universitaetsklinikum Erlangen ( Site 0303), Erlangen, Bayern, Germany|Klinikum Rechts der Isar ( Site 0300), Muenchen, Bayern, Germany|Universitaetsklinik der Paracelsus Medizinischen Privatuniversitaet ( Site 0318), Nuernberg, Bayern, Germany|Universitaetsklinikum Duesseldorf ( Site 0306), Duesseldorf, Nordrhein-Westfalen, Germany|Krankenhaus der Barmherzigen Brueder Trier ( Site 0310), Trier, Rheinland-Pfalz, Germany|Universitaetsklinikum Jena ( Site 0305), Jena, Thuringen, Germany|Charite Universitaetsmedizin Berlin ( Site 0301), Berlin, Germany|Tallaght University Hospital ( Site 0730), Dublin, Ireland|Mid Western Cancer Centre ( Site 0728), Limerick, Ireland|Meir Medical Center ( Site 0544), Kfar Saba, Central, Israel|Assaf Harofe ( Site 0547), Be'er- Ya'akov, HaMerkaz, Israel|Rabin Medical Center ( Site 0545), Petach-Tikwa, HaMerkaz, Israel|Ha Emek Medical Center ( Site 0548), Afula, HaTsafon, Israel|Soroka Medical Center ( Site 0549), Beer Sheva, Southern, Israel|Chaim Sheba Medical Center ( Site 0541), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 0542), Tel-Aviv, Tell Abib, Israel|Rambam Medical Center ( Site 0543), Haifa, Israel|Hadassah Ein Kerem Medical Center ( Site 0546), Jerusalem, Israel|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0462), Meldola, Forli-Cesena, Italy|Istituto Clinico Humanitas Research Hospital ( Site 0452), Rozzano, Milano, Italy|Medical Oncology Ospedale San Donato ( Site 0461), Arezzo, Italy|Policlinico S.Orsola-Malpighi ( Site 0453), Bologna, Italy|Azienda Ospedaliera Cannizzaro ( Site 0458), Catania, Italy|Azienda Ospedaliera San Camillo Forlanini ( Site 0455), Roma, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0463), Roma, Italy|Azienda Ospedaliera Santa Maria Terni ( Site 0456), Terni, Italy|Presidio Ospedaliero Santa Chiara ( Site 0451), Trento, Italy|Fujita Health University Hospital ( Site 0724), Toyoake, Aichi, Japan|National Cancer Center Hospital East ( Site 0702), Kashiwa, Chiba, Japan|Toho University Sakura Medical Center ( Site 0703), Sakura, Chiba, Japan|National Hospital Organization Shikoku Cancer Center ( Site 0716), Matsuyama, Ehime, Japan|Kobe City Medical Center General Hospital ( Site 0726), Kobe, Hyogo, Japan|Kanazawa University Hospital ( Site 0701), Kanazawa, Ishikawa, Japan|Kitasato University Hospital ( Site 0705), Sagamihara, Kanagawa, Japan|Yokohama City University Medical Center ( Site 0706), Yokohama, Kanagawa, Japan|Nara Medical University Hospital ( Site 0715), Kashihara, Nara, Japan|Kindai University Hospital ( Site 0714), Osakasayama, Osaka, Japan|Osaka University Hospital ( Site 0713), Suita, Osaka, Japan|Saitama Medical University International Medical Center ( Site 0708), Hidaka, Saitama, Japan|Dokkyo Medical University Saitama Medical Center ( Site 0707), Koshigaya, Saitama, Japan|Fuji City General Hospital ( Site 0725), Fuji, Shizuoka, Japan|Hamamatsu University Hospital ( Site 0720), Hamamatsu, Shizuoka, Japan|Yamaguchi University Hospital ( Site 0717), Ube, Yamaguchi, Japan|Chiba Cancer Center ( Site 0704), Chiba, Japan|Kyushu University Hospital ( Site 0718), Fukuoka, Japan|University of Miyazaki Hospital ( Site 0721), Miyazaki, Japan|Nagano Municipal Hospital ( Site 0723), Nagano, Japan|Nagasaki University Hospital ( Site 0719), Nagasaki, Japan|Osaka International Cancer Institute ( Site 0722), Osaka, Japan|Toranomon Hospital ( Site 0711), Tokyo, Japan|Nippon Medical School Hospital ( Site 0709), Tokyo, Japan|Keio University Hospital ( Site 0710), Tokyo, Japan|Chonnam National University Hwasun Hospital ( Site 0174), Hwasun Gun, Jeonranamdo, Korea, Republic of|National Cancer Center ( Site 0176), Goyang-si, Kyonggi-do, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 0173), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Asan Medical Center ( Site 0171), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center ( Site 0172), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Medisch Centrum Leeuwarden ( Site 0477), Leeuwarden, Fryslan, Netherlands|Radboud University Medical Center ( Site 0470), Nijmegen, Gelderland, Netherlands|Antoni van Leeuwenhoek Ziekenhuis ( Site 0480), Amsterdam, Noord-Holland, Netherlands|Vrije Universiteit Medisch Centrum ( Site 0479), Amsterdam, Noord-Holland, Netherlands|Spaarne Ziekenhuis ( Site 0473), Hoofddorp, Noord-Holland, Netherlands|Ziekenhuisgroep Twente ( Site 0469), Almelo, Overijssel, Netherlands|Medisch Centrum Haaglanden ( Site 0471), Leidschendam, Zuid-Holland, Netherlands|Erasmus MC ( Site 0475), Rotterdam, Zuid-Holland, Netherlands|Franciscus Gasthuis en Vlietland ( Site 0489), Schiedam, Zuid-Holland, Netherlands|Auckland City Hospital ( Site 0193), Auckland, New Zealand|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565), Chelyabinsk, Chelyabinskaya Oblast', Russian Federation|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0585), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|Russian Scientific Center of Roentgenoradiology ( Site 0559), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 0562), Moscow, Moskva, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 0568), Omsk, Omskaya Oblast', Russian Federation|SBHI Samara Regional Clinical Oncology Dispensary ( Site 0576), Samara, Samarskaya Oblast', Russian Federation|SBHI Leningrad Regional Oncology Dispensary ( Site 0588), Saint Petersburg, Sankt-Peterburg, Russian Federation|Clinical Research Center of specialized types medical care-Oncology ( Site 0570), Saint Petersburg, Sankt-Peterburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies ( Site 0567), Saint Petersburg, Sankt-Peterburg, Russian Federation|Tomsk National Scientific Medical Center of Russian Academy of Science ( Site 0579), Tomsk, Tomskaya Oblast', Russian Federation|Hospital del Mar ( Site 0333), Barcelona, Barcelona [Barcelona], Spain|Hospital General Universitari Vall d Hebron ( Site 0334), Barcelona, Barcelona [Barcelona], Spain|Hospital Clinic ( Site 0323), Barcelona, Barcelona [Barcelona], Spain|Instituto Catalan de Oncologia - ICO ( Site 0330), L Hospitalet De Llobregat, Barcelona [Barcelona], Spain|Hospital Parc Tauli ( Site 0335), Sabadell, Barcelona [Barcelona], Spain|Hospital Josep Trueta ( Site 0321), Girona, Girona [Gerona], Spain|Hospital Quiron Madrid ( Site 0325), Pozuelo de Alarcon, Madrid, Spain|Hospital San Pedro de Alcantara ( Site 0326), Caceres, Spain|Hospital Universitario Virgen de la Victoria ( Site 0337), Malaga, Spain|National Cheng Kung University Hospital ( Site 0134), Tainen, Tainan, Taiwan|China Medical University Hospital ( Site 0132), Taichung, Taiwan|Taichung Veterans General Hospital ( Site 0133), Taichung, Taiwan|National Taiwan University Hospital ( Site 0131), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 0135), Taipei, Taiwan|University Hospitals Bristol NHS Foundation Trust ( Site 0530), Bristol, Bristol, City Of, United Kingdom|Cambridge University Hospitals NHS Trust ( Site 0540), Cambridge, Cambridgeshire, United Kingdom|Musgrove Park Hospital ( Site 0537), Taunton, Somerset, United Kingdom|University of North Midlands NHS Foundation Trust ( Site 0527), Stoke-on-Trent, Staffordshire, United Kingdom|Mount Vernon Cancer Centre ( Site 0536), Northwood, United Kingdom|Royal Marsden Hospital ( Site 0526), Sutton, United Kingdom",7151102,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,OVARIAN CANCER,_ENZALUTAMIDE,NCT03464201,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Mar, Barcelona, Spain|Hospital Reina Sofia, Córdoba, Spain|Hospital Madrid Sanchinarro (CIOCC), Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital de Navarra, Pamplona, Spain|Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Hospital La Fe, Valencia, Spain",7709517,C07D233/70,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,OVARIAN CANCER,_CYCLOPHOSPHAMIDE,NCT03814447,Early Phase 1,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai 6th People's Hospital, Shanghai, Shanghai, China",3987166,7,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,OVARIAN CANCER,_FLUDARABINE,NCT03814447,Early Phase 1,Recruiting,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai 6th People's Hospital, Shanghai, Shanghai, China",7547776,C07H19/16,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,PROSTATE CANCER,_CYCLOPHOSPHAMIDE,NCT03089203,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania, Philadelphia, Pennsylvania, United States",3987166,7,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,END STAGE RENAL DISEASE,_EVEROLIMUS,NCT03413722,,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Observational Model: Cohort|Time Perspective: Prospective,"University of Kansas Medical Center, Kansas City, Kansas, United States",5665772,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PROSTATE CANCER,_HYDROCORTISONE,NCT00859781,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arizona Cancer Center, Tucson, Arizona, United States|Cedars Sinai, Los Angeles, California, United States|USC/Norris Comprehensive cancer center, Los Angeles, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Florida, Orlando Health, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Weill Cornell Medical College, New York, New York, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States",5635497,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,PROSTATE CANCER,_KETOCONAZOLE,NCT00859781,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arizona Cancer Center, Tucson, Arizona, United States|Cedars Sinai, Los Angeles, California, United States|USC/Norris Comprehensive cancer center, Los Angeles, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Florida, Orlando Health, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|North Shore Hematology Oncology Associates, East Setauket, New York, United States|Weill Cornell Medical College, New York, New York, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States",5456851,A61K8/49,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,14.0,18.103041130208002,2611.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.3,531.431,69.06,6.0,0.0,5.0,54.83,138.07,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,PROSTATIC NEOPLASMS,_PREDNISOLONE,NCT04034095,,Recruiting,Male,"20 Years and older   (Adult, Older Adult)",Industry,Observational Model: Cohort|Time Perspective: Prospective,"Akita University Hospital, Akita, Japan|Juntendo University Hospital, Bunkyo-Ku, Japan|Tokyo Medical and Dental University Hospital, Bunkyo-Ku, Japan|The University of Tokyo Hospital, Bunkyo, Japan|Chiba University Hospital, Chiba, Japan|Chiba Cancer Center, Chiba, Japan|University of Yamanashi Hospital, Chuo, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gifu University Hospital, Gifu, Japan|Harasanshin Hospital, Hakata-Ku, Japan|Hamamatsu Medical University Hospital, Hamamatsu, Japan|Saitama Medical University International Medical Center, Hidaka, Japan|Kansai Medical University Hospital, Hirakata, Japan|Hirosaki University Hospital, Hirosaki, Japan|Hiroshima University Hospital, Hiroshima, Japan|University of Occupational and Environmental Health, Hukuoka, Japan|Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan|Tokyo Medical University Ibaraki Medical Center, Inashiki, Japan|Kanazawa Medical University Hospital, Kahoku-District, Japan|Kyoto Prefectural University of Medicine Hospital, Kamigyo, Japan|St.Marianna University School of Medicine, Kanagawa, Japan|Kanazawa University Hospital, Kanazawa, Japan|Nara Medical University Hospital, Kashihara, Japan|Kimitsu Chuo Hospital, Kisarazu, Japan|Kagawa University Hospital, Kita-Gun, Japan|Kobe City Medical Center General Hospital, Kobe-City,, Japan|Kobe University Hospital, Kobe, Japan|Kochi Medical School Hospital, Kochi, Japan|Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan|The Cancer Institute Hospital of JFCR, Koto-Ku, Japan|NHO Shikoku Cancer Center, Matsuyama-Shi, Japan|Kitasato University Hospital, Minami-Ku, Sagamihara-Shi, Japan|Kyorin University Hospital, Mitaka, Japan|University of Miyazaki Hospital, Miyazaki, Japan|Iwate Medical University Hospital, Morioka, Japan|Aichi Medical University Hospital, Nagakute, Japan|Nagano Municipal Hospital, Nagano, Japan|Nagasaki University Hospital, Nagasaki, Japan|Nagoya University Hospital, Nagoya, Japan|Nagoya City University Hospital, Nagoya, Japan|University of the Ryukyus Hospital, Nakagami gun, Japan|Tokyo Metropolitan Police Hospital, Nakano-ku, Japan|Miyagi Cancer Center, Natori-shi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City University Hospital, Osaka-City, Japan|Kindai University Hospital, Osaka-Sayama, Japan|Osaka International Cancer Institute, Osaka-Shi, Japan|Osaka University Hospital, Osaka, Japan|Toho University Medical Center Omori Hospital, Ota, Japan|Gunma Prefectural Cancer Center, Ota, Japan|Shiga University of Medical Science Hospital, Otsu, Japan|Saitama Medical Center, Saitama, Japan|Sapporo Medical University Hospital, Sapporo, Japan|Hokkaido University Hospital, Sapporo, Japan|Tohoku University Hospital, Sendai, Japan|Tohoku Medical And Pharmaceutical University Hospital, Sendai, Japan|Jichi Medical University Hospital, Shimotsuke, Japan|Showa University Hospital, Shinagawa, Japan|JCHO Tokyo Shinjuku Medical Center, Shinjuku-ku, Japan|Chutoen General Medical Center, Shizuoka, Japan|Osaka Medical College Hospital, Takatsuki, Japan|Tokushima University Hospital, Tokushima, Japan|Toranomon Hospital, Tokyo, Japan|The Jikei University Hospital, Tokyo, Japan|Nippon Medical School Hospital, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Teikyo University Hospital, Tokyo, Japan|Ehime University Hospital, Toon, Japan|Toyama University Hospital, Toyama-shi, Japan|Fujita Health University Hospital, Toyoake, Japan|Mie University Hospital, Tsu, Japan|Yamaguchi University Hospital, Ube, Japan|Wakayama Medical University Hospital, Wakayama, Japan|Yamagata University Hospital, Yamagata, Japan|Yokohama Rosai Hospital, Yokohama, Japan|Yokohama City University Medical Center, Yokohama, Japan|Yokohama City University Hospital, Yokohama, Japan|Yokosuka Kyosai Hospital, Yokosuka, Japan|Tottori University Hospital, Yonago, Japan|University of Fukui Hospital, Yoshida, Japan|Oita University Hospital, Yufu, Japan",5178878,A61K9/0056,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,PROSTATE CANCER,_HYDROXYCHLOROQUINE,NCT03513211,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St Vincent's Hospital, Darlinghurst, New South Wales, Australia",4181725,2,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,HYSTERECTOMY,_DEXTROSE,NCT03719755,Not Applicable,Recruiting,Female,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Mayo Clinic, Scottsdale, Arizona, United States",3964974,C12Q1/54,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,ENDOMETRIOSIS,_CABERGOLINE,NCT03928288,Phase 2,Recruiting,Female,"15 Years to 40 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States",5705510.0,4,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,26.415326803425106,154.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.97,451.6043,71.68,4.0,2.0,4.0,52.5,133.5,8.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,MUCOSITIS,_FOLIC_ACID,NCT03581773,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aarhus University Hospital, Department of oncology, Aarhus, Central Region Of Denmark, Denmark|Department of Oncology, Herlev Hospital, Herlev, Denmark|Department of Oncology, Odense University Hospital, Odense, Denmark",3960757.0,A61K9/1694,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
C[N+](C)(C)CCO,GESTATIONAL DIABETES,_CHOLINE,NCT04302168,Not Applicable,Recruiting,Female,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Maimonides Medical Center, Brooklyn, New York, United States",,,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.6,104.1708,20.23,1.0,1.0,0.0,12.57,42.19,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ccnc2cc1OCC1(N)CC1,OVARIAN CANCER,_ANLOTINIB,NCT03924882,Phase 2,Recruiting,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China",8148532,C07D239/88,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,49.315181009877,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.7,407.445,82.39,4.0,2.0,5.0,42.95,110.65,6.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,OVARIAN CANCER,_DOXORUBICIN_HYDROCHLORIDE,NCT04337632,Phase 3,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hunan Cancer Hospital, Changsha, Hunan, China",4003996,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
CC1=C[C@H](O)CC(C)(C)[C@H]1/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C,PROSTATE CANCER,_LUTEIN,NCT04136353,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|GenesisCare Newcastle, Newcastle, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|St Vincent's Public Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Northern Cancer Institute, Sydney, New South Wales, Australia|Sydney Adventist Hospital, Sydney, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Campbelltown hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|ROPART, Brisbane, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Icon Cancer Centre, Southport, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Peter MacCallum Cancer Centre - Bendigo Campus, Bendigo, Victoria, Australia|Peter MacCallum Cancer Centre (Moorabbin Campus), Bentleigh East, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Palmerston North Hospital, Palmerston North, New Zealand",3932546.0,C07C11/21,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,17.0,23.1298383950389,1374.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.29,568.886,40.46,2.0,2.0,2.0,73.81,195.06,10.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,PROSTATE CANCER,_DAROLUTAMIDE,NCT04136353,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|GenesisCare Newcastle, Newcastle, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|St Vincent's Public Hospital, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Chris O'Brien Lifehouse, Sydney, New South Wales, Australia|Northern Cancer Institute, Sydney, New South Wales, Australia|Sydney Adventist Hospital, Sydney, New South Wales, Australia|Liverpool Hospital, Sydney, New South Wales, Australia|St George Hospital, Sydney, New South Wales, Australia|Campbelltown hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|ROPART, Brisbane, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Icon Cancer Centre, Southport, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Peter MacCallum Cancer Centre - Bendigo Campus, Bendigo, Victoria, Australia|Peter MacCallum Cancer Centre (Moorabbin Campus), Bentleigh East, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Auckland City Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Palmerston North Hospital, Palmerston North, New Zealand",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,52.403540113760045,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,398.85,119.62,5.0,3.0,3.0,41.86,117.16,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,PROSTATE CANCER,_CURCUMIN,NCT03769766,Phase 3,Recruiting,Male,"40 Years to 89 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","UT Southwestern Medical Center, Dallas, Texas, United States",4138212,C09B61/00,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,HIV INFECTION,_CAFFEINE,NCT04425902,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Las Vegas, Nevada, United States",5972916.0,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,HIV INFECTION,_PRAVASTATIN,NCT04425902,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Las Vegas, Nevada, United States",5622985.0,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
COCCc1ccc(OCC(O)CNC(C)C)cc1,HIV INFECTION,_METOPROLOL,NCT04425902,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Las Vegas, Nevada, United States",9504655.0,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,HIV INFECTION,_OMEPRAZOLE,NCT04425902,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Las Vegas, Nevada, United States",5690960.0,4,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,HIV INFECTION,_MONTELUKAST,NCT04425902,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Las Vegas, Nevada, United States",8007830.0,A61K9/1623,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,HIV INFECTION,_MIDAZOLAM,NCT04425902,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Las Vegas, Nevada, United States",8217033,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O,HIV INFECTION,_DIGOXIN,NCT04425902,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Las Vegas, Nevada, United States",3933997.0,G01N31/16,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,22.6698700178648,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.04,780.9385,203.06,13.0,6.0,8.0,84.8,193.23,7.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0
CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1,HIV INFECTION,_FLURBIPROFEN,NCT04425902,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Las Vegas, Nevada, United States",3973037,1,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,5.0,17.840202057537102,2498.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.57,244.2609,37.3,2.0,1.0,2.0,25.23,67.29,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CN(C)C(=N)NC(=N)N,PREECLAMPSIA,_METFORMIN,NCT03717701,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",6288095.0,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,PREECLAMPSIA,_ESOMEPRAZOLE,NCT03717701,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",5900424,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,CHRONIC KIDNEY DISEASE,_FRUCTOSE,NCT01407627,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","University of Calgary, Calgary, Alberta, Canada",WO-2006138705-A1,A23L7/1963 ,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,180.1559,110.38,6.0,5.0,1.0,16.29,36.36,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,PREECLAMPSIA,_PRAVASTATIN,NCT03648970,Phase 2,Recruiting,Female,"15 Years to 45 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Sanglah General Hospital, Denpasar, Bali, Indonesia|Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia|Ramelan Naval Hospital, Surabaya, East Java, Indonesia|Dr. Soetomo Hospital, Surabaya, East Java, Indonesia|Adam Malik General Hospital, Medan, North Sumatra, Indonesia|Dr. Wahidin Sudirohusodo General Hospital, Makasar, South Sulawesi, Indonesia|Hasan Sadikin General Hospital, Bandung, West Java, Indonesia",5622985.0,4,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,OVARIAN CANCER,_ROSUVASTATIN,NCT03532139,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",RE37314,C07D239/42 ,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHRONIC KIDNEY DISEASE,_DASATINIB,NCT02848131,Phase 2,Enrolling by invitation,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",6596746,C07D491/113,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,CHRONIC KIDNEY DISEASE,_QUERCETIN,NCT02848131,Phase 2,Enrolling by invitation,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Rochester, Rochester, Minnesota, United States",4211772,C07H17/07,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,25.232550976406003,3241.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.81,302.2357,127.45,7.0,5.0,3.0,28.54,76.86,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,HIV INFECTION,_PANOBINOSTAT,NCT02471430,Phase 1|Phase 2,Recruiting,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States",6552065,C07D471/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,27.0,19.680075566233302,88.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.16,349.434,77.15,3.0,4.0,3.0,38.94,105.5,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,PROSTATE CANCER,_ABEMACICLIB,NCT03706365,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Arizona Cancer Center, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|St. Bernards Medical Center, Jonesboro, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|University of California - San Diego, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States|Pacific Cancer Care, Monterey, California, United States|Ridley- Tree Cancer Center, Santa Barbara, California, United States|Rocky Mountain Cancer Center, Lone Tree, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Millennium Oncology, Hollywood, Florida, United States|Cancer Care Center of Brevard, Palm Bay, Florida, United States|Northside Hospital Cancer Institute, Marietta, Georgia, United States|Fort Wayne Medical Oncology & Hematology, Inc., Fort Wayne, Indiana, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Southcoast Centers for Cancer Care, Fairhaven, Massachusetts, United States|University of Minnesota Hospital, Minneapolis, Minnesota, United States|Research Medical Center, Kansas City, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|New York Oncology Hematology, P.C, Albany, New York, United States|Associated Medical Professionals of NY, Syracuse, New York, United States|Oklahoma Cancer Specialists & Research Institute, LLC, Tulsa, Oklahoma, United States|Northwest Cancer Specialists PC, Tigard, Oregon, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Southwestern Medical Center - Dallas, Dallas, Texas, United States|Texas Oncology Fort Worth, Fort Worth, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, United States|Scott & White Memorial Hospital & Clinic, Temple, Texas, United States|US Oncology, The Woodlands, Texas, United States|Texas Oncology Cancer Care and Research Center, Waco, Texas, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Southside Cancer Care Centre, Kogarah, New South Wales, Australia|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia|Finsen Institute, Copenhagen, Denmark|Næstved Sygehus, Næstved, Denmark|Studienpraxis Urologie, Nürtingen, Baden-Württemberg, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Asan Medical Center, Seoul, Kr-11, Korea, Republic of|Samsung Medical Center, Seoul, Kr-11, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Canisius-Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Erasmus Medisch Centrum, Rotterdam, South Holland, Netherlands|St. Antonius Ziekenhuis, locatie Nieuwegein, Utrecht, Netherlands|Puerto Rico Hematology/Oncology Group, Bayamon, Puerto Rico|Centrul de Oncologie Sf. Nectarie SRL, Craiova, Dolj, Romania|S.C. R.T.C. Radiology Therapeutic Center S.R.L., Otopeni, Ilfov, Romania|SC Gral Medical SRL, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta, Constanta, Romania|Hospital Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Derriford Hospital, Plymouth, Devon, United Kingdom|University College Hospital - London, London, Greater London, United Kingdom|Charing Cross Hospital, Chelsea, London, United Kingdom|Northampton General Hospital, Northampton, United Kingdom",7855211,C07D401/14,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,PROSTATE CANCER,_IBRUTINIB,NCT02643667,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, San Francisco, California, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",7514444,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,INFERTILITY,_DOXYCYCLINE,NCT03824340,Not Applicable,Recruiting,Female,20 Years to 42 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Algazeerah, Giza, Egypt",5789395.0,6,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,PCOS,_DAPAGLIFLOZIN,NCT04213677,Phase 3,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China",6956026,A61K47/12,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,PREECLAMPSIA,_SILDENAFIL,NCT03724838,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",5250534.0,C07D487/04,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12.O=C(O)CC(O)(CC(=O)O)C(=O)O,PREECLAMPSIA,_SILDENAFIL_CITRATE,NCT03724838,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Aswan University, Aswan, Egypt",WO-1999030688-A1,A61K9/19,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,45.0,32.7488,208.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,URINARY TRACT INFECTIONS,_ERTAPENEM,NCT03218800,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"INCA Instituto Nacional do Cancer, Rio de Janeiro, Brazil",5478820.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,26.7110207601798,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.2,475.515,156.27,8.0,5.0,4.0,48.77,121.8,7.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
Oc1ncnc2[nH]ncc12,CHRONIC KIDNEY DISEASE,_ALLOPURINOL,NCT03990363,Phase 2,Recruiting,All,"18 Years to 130 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Huntsville, Alabama, United States|Research Site, Bakersfield, California, United States|Research Site, Canyon Country, California, United States|Research Site, Irvine, California, United States|Research Site, Irvine, California, United States|Research Site, Long Beach, California, United States|Research Site, Moorpark, California, United States|Research Site, Northridge, California, United States|Research Site, Orange, California, United States|Research Site, Vacaville, California, United States|Research Site, Victorville, California, United States|Research Site, Denver, Colorado, United States|Research Site, Bloomfield, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ocoee, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Wauconda, Illinois, United States|Research Site, Paducah, Kentucky, United States|Research Site, Takoma Park, Maryland, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Saint Clair Shores, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Gallup, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Jamaica, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Asheville, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Goose Creek, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lampasas, Texas, United States|Research Site, Lewisville, Texas, United States|Research Site, Pearland, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Shavano Park, Texas, United States|Research Site, Alexandria, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chenzhou, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Hangzhou, China|Research Site, Nan Jin, China|Research Site, Nanchang, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Frydek, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 6, Czechia|Research Site, Slany, Czechia|Research Site, Třebíč, Czechia|Research Site, Annonay, France|Research Site, Brest Cedex, France|Research Site, Grenoble cedex 9, France|Research Site, Marseille cedex 5, France|Research Site, Montpellier, France|Research Site, Nimes, France|Research Site, Paris cedex 15, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Rouen, France|Research Site, Tours, France|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyula, Hungary|Research Site, Hatvan, Hungary|Research Site, Kaposvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szeged, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Afula, Israel|Research Site, Ashdod, Israel|Research Site, Ashkelon, Israel|Research Site, Beer Sheba, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Kfar Sava, Israel|Research Site, Nahariya, Israel|Research Site, Nazareth, Israel|Research Site, Petach-Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Rehovot, Israel|Research Site, Safed, Israel|Research Site, Tel-Aviv, Israel|Research Site, Tiberias, Israel|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Cremona, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Celaya, Mexico|Research Site, Ciudad Madero, Mexico|Research Site, Cuernavaca, Mexico|Research Site, Estado de Mexico, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, Tijuana, Mexico|Research Site, Veracruz, Mexico|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Olesnica, Poland|Research Site, Poznań, Poland|Research Site, Rzeszów, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Deva, Romania|Research Site, Galati, Romania|Research Site, Hunedoara, Romania|Research Site, Iasi, Romania|Research Site, Iaşi, Romania|Research Site, Oradea, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania|Research Site, Satu-Mare, Romania|Research Site, Tg Mures, Romania|Research Site, Timisoara, Romania|Research Site, Timișoara, Romania|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Hlohovec, Slovakia|Research Site, Koshice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kralovsky Chlmec, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Puchov, Slovakia|Research Site, Rimavská Sobota, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Krugersdorp, South Africa|Research Site, Lenasia, South Africa|Research Site, Paarl, South Africa|Research Site, Stanger, South Africa|Research Site, Stellenbosch, South Africa|Research Site, Tshwane, South Africa|Research Site, Worcester, South Africa|Research Site, Alicante, Spain|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Burela, Spain|Research Site, Ciudad Real, Spain|Research Site, Cordoba, Spain|Research Site, Girona, Spain|Research Site, Granada, Spain|Research Site, L'Hospitalet De Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Puerto De Sagunto, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain",8084483.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,PROSTATE CANCER,_CARVEDILOL,NCT02944201,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States",6022562,A61K9/5026,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C([O-])O.[Na+],CHRONIC KIDNEY DISEASE,_SODIUM_BICARBONATE,NCT02411773,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Atlanta VA Medical Center, Decatur, Georgia, United States",5840737,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,28.32091008028911,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.06,84.0066,60.36,3.0,1.0,0.0,3.86,20.34,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
O=C(O)O,CHRONIC KIDNEY DISEASE,_BICARBONATE,NCT02411773,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Atlanta VA Medical Center, Decatur, Georgia, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,PREECLAMPSIA,_OXYTOCIN,NCT02221830,Early Phase 1,Recruiting,Female,"13 Years to 45 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Colorado Clinical and Translational Research Center, Aurora, Colorado, United States",3943246,A61K38/095,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1,PROSTATE CANCER,_ROCURONIUM,NCT03808077,Phase 2,Recruiting,Male,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Memorial Sloan - Kettering Cancer Center, New York, New York, United States",5962536,1,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,14.1604550401445,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.71,529.7742,59.0,4.0,1.0,6.0,62.78,161.65,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],DIABETIC NEPHROPATHY,_MAGNESIUM_CITRATE,NCT03824379,Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ain Shams University Hospitals, Cairo, Abbasseia, Egypt",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.08,451.11300000000006,140.62,7.0,1.0,0.0,14.25,68.14,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21,PROSTATE CANCER,_SAVOLITINIB,NCT03385655,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Jewish General Hospital, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada",US-20140255428-A1,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,16.0,15.8360541284215,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,345.37,91.61,6.0,0.0,5.0,35.72,119.06,3.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,OVARIAN CANCER,_TOPOTECAN,NCT03763123,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Cancer Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|The first affiliated hospital,sun yat-sen university, Guangzhou, Guangdong, China|the Affiliated Cancer Hospital of Harbin Medical University, Harbin, Hei Longjiang, China|Hunan Cancer Hospital, Changsha, Hunan, China|Wuhan Union Hospital, Wuhan, Hunan, China",5004758,C07D491/22,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,END STAGE RENAL DISEASE,_EMPAGLIFLOZIN,NCT03713190,Phase 2,Recruiting,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy",6303661,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,CHRONIC KIDNEY DISEASE,_EMPAGLIFLOZIN,NCT03594110,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Nephrology Consultants, LLC, Huntsville, Alabama, United States|Aventiv Research Inc., Mesa, Arizona, United States|Renal Consultants Medical Group, Granada Hills, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|University of California Los Angeles, Sylmar, California, United States|University of California Los Angeles, Torrance, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Chase Medical Research, LLC, Thomaston, Connecticut, United States|Midland Florida Clinical Reearch Center, LLC, DeLand, Florida, United States|University of Florida, Gainesville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|East Coast Clinical Research, Inc, Lake City, Florida, United States|Total Research Group, LLC, Miami, Florida, United States|Hanson Clinical Research Center, Port Charlotte, Florida, United States|Emory University, Atlanta, Georgia, United States|Atlanta VA Health Care System, Decatur, Georgia, United States|The Jones Center for Diabetes and Endocrine Wellness, Macon, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Saint Elizabeth Healthcare, Covington, Kentucky, United States|Lexington VA Health Care System - Troy Bowling Campus, Lexington, Kentucky, United States|Medstar Health Research Institute, Baltimore, Maryland, United States|Kidney Care and Transplant Services of New England, PC, Springfield, Massachusetts, United States|Saint Clair Specialty Physicians, Roseville, Michigan, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Seacoast Kidney and Hypertension Specialists, Portsmouth, New Hampshire, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Mountain Kidney and Hypertension Associates, PA, Asheville, North Carolina, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Brookview Hills Research Associates LLC, Winston-Salem, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Dayton VA Medical Center, Ohio, Dayton, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Carolina Diabetes & Kidney Center, Sumter, South Carolina, United States|Regional Health Clinical Research, Rapid City, South Dakota, United States|Research Institute of Dallas, Dallas, Texas, United States|Renal Disease Research Institute, Dallas, Texas, United States|Academy Of Diabetes, Thyroid And Endocrine, PA, El Paso, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|P&I Clinical Research, LLC, Lufkin, Texas, United States|Texas Institute for Kidney and Endocrine Disorders, Lufkin, Texas, United States|Clinical Advancement Center PLLC, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Utah Health Sciences Center, Salt Lake City, Utah, United States|Salem VA Medical Center, Salem, Virginia, United States|Providence Medical Research Center, Spokane, Washington, United States|Kelowna General Hospital, Kelowna, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|LMC Clinical Research Inc. (Brampton), Brampton, Ontario, Canada|Cambridge Cardiac Care Inc., Cambridge, Ontario, Canada|LMC Clinical Research Inc. (Thornhill), Concord, Ontario, Canada|LMC Endocrinology Centres (Etobicoke) Ltd., Etobicoke, Ontario, Canada|Clinical Research Solutions Inc., Kitchener, Ontario, Canada|London Health Science Centre, University Campus, London, Ontario, Canada|LMC Clinical Research Inc. (Ottawa), Nepean, Ontario, Canada|Lakeridge Health Oshawa, Oshawa, Ontario, Canada|LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Fadia El Boreky Medicine Professional, Waterloo, Ontario, Canada|Montreal Clinical Research Institute (IRCM), Montreal, Quebec, Canada|Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|CHU de Quebec-Universite Laval Research Centre, Quebec, Canada|IUCPQ (Laval University), Quebec, Canada|Beijing AnZhen Hospital, Beijing, China|Cardiovascular Institute and Fu Wai Hospital, Beijing, China|Xiangya Hospital, Central South University, Changsha, China|Xinqiao Hospital, Chongqing, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China|Jinling Hospital, Nanjing, China|Shanghai Fifth People's Hospital affiliated to Fudan University, Shanghai, China|Shenzhen People's Hospital, Shenzhen, China|Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China|People's Hospital of Sichuan Province, Sichuan, China|SuZhou Kowloon Hospital, Suzhou, China|Wuhan Fourth Hospital, Wuhan, China|Henan Provincial People's Hospital, Zhengzhou, China|Zhuzhou Central Hospital, Zhuzhou, China|Zhuzhou Central Hospital, Zhuzhou, China|Studienzentrum Aschaffenburg, Aschaffenburg, Germany|Universitätsklinikum Augsburg, Augsburg, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Bad Oeynhausen, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Ärztezentrum Helle Mitte, Berlin, Germany|Klinikum Bielefeld gGmbH, Bielefeld, Germany|Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Germany|ClinPhenomics GmbH & Co KG, Frankfurt, Frankfurt, Germany|Nierenzentrum Freiburg, Freiburg, Germany|Nephrologisches Zentrum Göttingen, Göttingen, Germany|Universitätsklinikum Halle/S., Halle, Germany|Zentrum für Nieren-, Hochdruck und Stoffwechselerkrankungen, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Dialysezentrum Heilbronn ÜBAG für Nephrologie und Dialyse, Heilbronn, Germany|Nephrologisches Zentrum Hoyerswerda, Hoyerswerda, Germany|Universitätsklinikum Jena, Jena, Germany|Städt. Klinikum, Karlsruhe, Moltkestr., Karlsruhe, Germany|Klinikum St. Georg gGmbH, Leipzig, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Mannheim GmbH, Mannheim, Germany|Nephrologisches Zentrum Mettmann, Mettmann, Germany|Klinikum der Universität München - Campus Innenstadt, München, Germany|Dialysezentrum Neckarsulm, Neckarsulm, Germany|KfH Kuratorium für Dialyse und Nierentransplantation e.V., Nürnberg, Germany|MVZ Diaverum Potsdam, Potsdam, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany|Universitätsklinikum Ulm, Ulm, Germany|Nephrologisches Zentrum Velbert, Velbert, Germany|MVZ DaVita Viersen GmbH, Viersen, Germany|Nephrologisches Zentrum Villingen-Schwenningen, Villingen-Schwenningen, Germany|Gemeinschaftspraxis für Nephrologie und Rheumatologie, Wiesbaden, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Osp. S. Giovanni di Dio, Firenze, Italy|Ospedale S. Cuore di Gesù, Gallipoli, Italy|Policlinico Gemelli, Roma, Italy|A.O. Univ. Integrata di Verona, Verona, Italy|Chubu Rosai Hospital, Aichi, Nagoya, Japan|Aichi Medical University Hospital, Aichi, Japan|Fukui Prefectural Hospital, Fukui City, Japan|Fukuoka University Hospital, Fukuoka, Fukuoka, Japan|Joumou Ohashi Clinic, Gumma, Maebashi, Japan|Maebashi Hirosegawa Clinic, Gunma, Japan|Ota Diabetes Clinic, Gunma, Japan|University of Tsukuba Hospital, Ibaraki, Tsukuba, Japan|Medical Corporation Seijinkai Ikeda Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|Koukan Clinic, Kawasaki, Japan|Kobe University Hospital, Kobe, Japan|Tohoku University Hospital, Miyagi, Sendai, Japan|Nagoya University Hospital, Nagoya, Japan|Kawasaki Medical School Hospital, Okayama, Kurashiki, Japan|Okayama University Hospital, Okayama, Okayama, Japan|AMC Nishi-umeda Clinic, Osaka, Japan|Kansai Electric Power Hospital, Osaka, Japan|Iwasaki Internal Medicine Clinic, Osaka, Japan|Shiga University of Medical Science Hospital, Shiga, Otsu, Japan|Juntendo University Hospital, Tokyo, Bunkyo-ku, Japan|The University of Tokyo Hospital, Tokyo, Bunkyo-ku, Japan|Shin Clinic, Tokyo, Ota-ku, Japan|Center Hospital of the National Center for Global Health and, Tokyo, Shinjuku-ku, Japan|Tokyo-Eki Center-building Clinic, Tokyo, Japan|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Ampang, Ampang, Malaysia|University Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia|Hospital Pulau Pinang, Georgetown, Pulau Pinang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Sultanah Aminah, Johor Bahru, Malaysia|Hospital Kajang, Kajang, Selangor, Malaysia|Hospital Serdang, Kajang, Selangor, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Trengganu, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Kulim, Kulim, Kedah, Malaysia|Hospital Melaka, Melaka, Malaysia|Hospital Pakar Sultanah Fatimah, Muar, Malaysia|Hospital Selayang, Selangor, Malaysia|Hospital Tuanku Ja'afar, Seremban, Negeri Sembilan, Malaysia|Pusat Perubatan UiTM Jalan Hospital, Sungai Buloh, Malaysia|Hospital Sultan Abdul Halim, Sungai Petani, Malaysia|Hospital Taiping, Taiping, Perak, Malaysia|Antrim Area Hospital, Antrim, United Kingdom|Ulster Hospital, Belfast, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital, Birmingham, United Kingdom|Oakenhurst Medical Practice, Blackburn, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Southmead Hospital, Bristol, United Kingdom|West Suffolk Hospital, Bury St Edmunds, United Kingdom|Kent & Canterbury Hospital, Oncology Department, Canterbury, Canterbury, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|St Helier Hospital, Carshalton, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darent Valley Hospital, Chemotherapy Unit, Dartford, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Dorset County Hospital, Dorchester, United Kingdom|Ninewells Hospital & Medical School, Dundee, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Gloucestershire Royal Hospital, Gloucester, United Kingdom|Hull Royal Infirmary, Hull, United Kingdom|Ipswich Hospital, Ipswich, United Kingdom|Queen Elizabeth Hospital, King's Lynn, United Kingdom|Victoria Hospital, Kirkcaldy, United Kingdom|St James's University Hospital, Leeds, United Kingdom|University Hospitals of Leicester, Leicester, United Kingdom|Aintree University Hospital, Liverpool, United Kingdom|Altnagelvin Area Hospital, Londonderry, United Kingdom|Royal London Hospital, London, United Kingdom|North Middlesex Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|King's College Hospital, London, United Kingdom|St George's Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Daisy Hill Hospital, Newry, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|St Bartholomew's Medical Centre (OxFed), Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Wessex Kidney Centre, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|Queen's Hospital, Romford, United Kingdom|Salford Royal Hospital, Salford, United Kingdom|Northern General Hospital, Sheffield, United Kingdom|University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom|Great Western Hospital, Swindon, United Kingdom|Princess Royal Hospital, Telford, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom",6303661,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,1.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,GESTATIONAL DIABETES,_EMPAGLIFLOZIN,NCT03215069,Phase 3,Recruiting,Female,20 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Leadership Sinai Centre foe Diabetes - Mount Sinai Hospital, Toronto, Ontario, Canada",6303661,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,END-STAGE RENAL DISEASE,_EPLERENONE,NCT02490904,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CHRU Besançon, Besancon, France|CHU Brest, Brest, France|CHU Dijon- Hôpital Bocage Central, Dijon, France|CHRU de Nancy, Nancy, France|CHU Reims-Hôpital Maison Blanche, Reims, France|CHU Saint Etienne, Saint-Étienne, France|NHC -CHRU Strasbourg, Strasbourg, France",6410524,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,105.0,31.639253372759104,243.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.67,414.4914,82.2,4.0,0.0,6.0,43.79,106.68,2.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,NEPHROTIC SYNDROME,_FUROSEMIDE,NCT03750136,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"II Department of Nephrology and Hypertension, Bialystok, Poland",3939713,G01N30/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,PROSTATIC NEOPLASMS,_ZOLPIDEM,NCT03436745,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States",6761910.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,CIRRHOSIS,_TADALAFIL,NCT03566914,Not Applicable,Recruiting,All,21 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dr Rakesh Kumar Jagdish, New Delhi, Delhi, India",5859006,C07D471/14,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,OVARIAN CANCER,_ZAFIRLUKAST,NCT04339140,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",4859692,C07D249/18,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,17.0,40.214378118647204,840.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.84,575.675,115.73,6.0,2.0,5.0,62.0,158.58,8.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],CORONARY ARTERY DISEASE,_FERUMOXYTOL,NCT02954510,Phase 3,Enrolling by invitation,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Brigham and Women's Hospital, Boston, Massachusetts, United States",6599498,B82Y5/00,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,PROSTATE CANCER,_TESTOSTERONE,NCT03716739,Phase 2,Recruiting,Male,"40 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","City of Hope, Duarte, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",5152997,A61K9/7084,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2OC(=O)CCC1CCCC1,PROSTATE CANCER,_TESTOSTERONE_CYPIONATE,NCT03716739,Phase 2,Recruiting,Male,"40 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","City of Hope, Duarte, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",5340584,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,32.0,18.661574159633602,315.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.1,412.61400000000003,43.37,2.0,0.0,5.0,49.87,119.36,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,PROSTATE CANCER,_TESTOSTERONE_ENANTHATE,NCT02090114,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sibley Memorial Hospital, Washington, District of Columbia, United States|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",8021335,A61M5/30,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,23.0,49.93942380747029,149.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.11,400.594,43.37,2.0,0.0,4.0,49.18,116.61,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0
C=CCN.ClCC1CO1,HYPERPHOSPHATEMIA,_SEVELAMER,NCT04551300,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital, Beijing, China",5496545,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,18.0,22.012772336187602,6.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.68,149.619,12.53,1.0,0.0,1.0,8.38,20.06,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
C=CC[NH3+].ClCC1CO1.O=C([O-])O,HYPERPHOSPHATEMIA,_SEVELAMER_CARBONATE,NCT04551300,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital, Beijing, China",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,ENDOMETRIOSIS,_INDOCYANINE_GREEN,NCT03950206,Not Applicable,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Diego Raimondo, Bologna, BO, Italy",6915154,A61B5/0261,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)C(=O)O,PROSTATE CANCER,_PYRUVATE,NCT02913131,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, San Francisco, San Francisco, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,PCOS,_SALSALATE,NCT03229408,Phase 2,Recruiting,Female,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Frank González, Chicago, Illinois, United States",3954533,C06B23/007,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,PREECLAMPSIA,_SALSALATE,NCT03482440,Early Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","University of Iowa, Iowa City, Iowa, United States|Pennsylvania State University, University Park, Pennsylvania, United States",3954533,C06B23/007,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
OC[C@H](O)[C@@H](O)[C@H](O)CO,END STAGE RENAL DISEASE,_XYLITOL,NCT04001036,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Nephrology, University of Chieti, Chieti, Italy",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.5,152.1458,101.15,5.0,5.0,0.0,14.42,32.44,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1,OVARIAN CANCER,_BRIVANIB,NCT03895788,Phase 1,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jing Wang, Changsha, Hunan, China",US-20040072832-A1,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,20.1400439434074,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.32,370.384,84.67,4.0,2.0,4.0,37.82,110.02,5.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,END STAGE RENAL DISEASE,_ETELCALCETIDE,NCT03795558,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Ordensklinikum Linz GmbH Elisabethinen, Linz, Upper Austria, Austria",8999932,C07K7/08,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,30.0,56.280416435655695,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.4,1048.26,557.71,23.0,22.0,0.0,108.23,303.63,36.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0
CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,SECONDARY HYPERPARATHYROIDISM|CHRONIC KIDNEY DISEASE,_ETELCALCETIDE,NCT03633708,Phase 3,Recruiting,All,"up to 18 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Kansas City, Missouri, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Kolkata, West Bengal, India|Research Site, Seoul, Korea, Republic of|Research Site, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Seremban, Negri Sembilan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Singapore, Singapore|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey",8999932,C07K7/08,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,30.0,56.280416435655695,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-3.4,1048.26,557.71,23.0,22.0,0.0,108.23,303.63,36.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0
CS(=O)(=O)OCCCCOS(C)(=O)=O,HIV INFECTIONS|AIDS,_BUSULFAN,NCT03517631,Phase 1,Recruiting,All,18 Years to 50 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",5430057,2,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PROSTATE CANCER,_OLAPARIB,NCT03810105,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of Chicago, Chicago, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States",7151102,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,GONORRHEA,_GENTAMICIN,NCT03294395,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Public Health Service, Amsterdam, Noord Holland, Netherlands",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,GONORRHEA,_ERTAPENEM,NCT03294395,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Public Health Service, Amsterdam, Noord Holland, Netherlands",5478820.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,26.7110207601798,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.2,475.515,156.27,8.0,5.0,4.0,48.77,121.8,7.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@@H]1O[C@@H]1P(=O)(O)O,GONORRHEA,_FOSFOMYCIN,NCT03294395,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Public Health Service, Amsterdam, Noord Holland, Netherlands",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.86,138.059,70.06,4.0,2.0,1.0,10.8,25.87,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.O=S(=O)(O)O,GONORRHEA,_GENTAMICIN_SULFATE,NCT03294395,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Public Health Service, Amsterdam, Noord Holland, Netherlands",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
NC(=O)c1cccnc1,PREECLAMPSIA,_NICOTINAMIDE,NCT03419364,Phase 2,Recruiting,Female,18 Years to 55 Years   (Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC at Chapel Hill, Chapel Hill, North Carolina, United States",3931207,C07D207/44,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,END STAGE RENAL DISEASE,_CHOLECALCIFEROL,NCT04145492,Phase 2|Phase 3,Recruiting,All,"6 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Radwa Maher El Borolossy, Cairo, Egypt",5994329.0,6,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CN(C)C(=N)NC(=N)N,HIV/AIDS,_METFORMIN,NCT04500678,Phase 2|Phase 3,Recruiting,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","John A. Burns School of Medicine, University of Hawaii - Manoa, Honolulu, Hawaii, United States",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,INFECTIVE ENDOCARDITIS,_DEXMEDETOMIDINE,NCT02698930,Not Applicable,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of",5344840,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0
Cc1ncc([N+](=O)[O-])n1CCO,BACTERIAL VAGINOSES,_METRONIDAZOLE,NCT03954990,Phase 1,Recruiting,Female,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Universty of Texas Medical Branch, Galveston, Texas, United States",5536743,4,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,ACUTE KIDNEY INJURY,_IOHEXOL,NCT02772276,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Riverside Clinical Research, Edgewater, Florida, United States|Orlando Clinical Research Center, Orlando, Florida, United States|Saint Louis University School of Medicine, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States",4278654,A61K49/0452,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,SEPTIC SHOCK,_FUROSEMIDE,NCT04156451,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Rumah Sakit Cipto Mangunkusumo, Jakarta Pusat, DKI Jakarta, Indonesia",3939713,G01N30/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,11.8606131542742,1299.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,330.744,122.63,5.0,3.0,2.0,30.55,77.47,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
C=Cc1c(C)c2cc3nc(cc4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CCC(=O)O)c(CCC(=O)OC)c4C)[C@@]1(C)C3=CC=C(C(=O)OC)[C@H]1C(=O)OC,RECURRENT PROSTATE CANCER,_VERTEPORFIN,NCT03067051,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Keith Cengel, Philadelphia, Pennsylvania, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust, London, United Kingdom",5214036.0,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,38.57163391445409,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.02,718.7942,173.56,7.0,3.0,6.0,81.29,199.08,12.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0
O=[As]O[As]=O,HIV/AIDS,_ARSENIC_TRIOXIDE,NCT03980665,Phase 1,Recruiting,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangzhou 8th People's Hospital, Guangzhou, Guangdong, China",6723351,5,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],KIDNEY STONES,_POTASSIUM_CITRATE,NCT03281928,Not Applicable,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Other","University of Chicago Medical Center, Chicago, Illinois, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.7,306.394,140.62,7.0,1.0,0.0,14.23,68.14,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,HIV/AIDS,_BICTEGRAVIR,NCT03789968,,Enrolling by invitation,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Retrospective,"Thomas Jefferson University, Philadelphia, Pennsylvania, United States",6703396,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,28.0,107.89543933140301,11.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.28,449.38599999999997,99.18,6.0,2.0,5.0,41.14,105.44,3.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,COVID-19,_ANGIOTENSIN_1-7,NCT04401423,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Columbia University Irving Medical Center, New York, New York, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-1.4,899.02,377.24,16.0,13.0,3.0,92.45,238.19,25.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
O=[N+]([O-])c1nccn1CC(O)CN1CCCCC1,PROSTATE CANCER,_PIMONIDAZOLE,NCT02095249,Not Applicable,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Health Network, Toronto, Ontario, Canada",5674693,G01N33/57492,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,11.0,42.678494424936794,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.58,254.29,84.43,5.0,1.0,2.0,25.32,65.83,5.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O,URINARY TRACT INFECTIONS,_D-MANNOSE,NCT03395288,Phase 2|Phase 3,Recruiting,Female,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention,"Washington University School of Medicine, Saint Louis, Missouri, United States",3935307,A61K8/73,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,19.9429146389042,1251.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,OVARIAN CANCER,_PALBOCICLIB,NCT03936270,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|CPO Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil|AC Camargo Cancer Center, São Paulo, Brazil|Hospital Beneficência Portuguesa, São Paulo, Brazil|Hospital Pérola Byington, São Paulo, Brazil|Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, Brazil",6936612,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,PROSTATE CANCER,_PALBOCICLIB,NCT02905318,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cross Cancer Institute, Edmonton, Alberta, Canada|BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Jewish General Hospital, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada",6936612,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,ENDOMETRIAL POLYP,_PROGESTERONE,NCT03309709,Phase 3,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Ospedale Pugliese Ciaccio, Catanzaro, Calabria, Italy|Federico II University, Naples, Italy",5543150.0,5,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)[O-],"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_ACETATE,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_PREDNISONE,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",6488960,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_ABIRATERONE,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",5604213,C07J41/0005,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_ABIRATERONE_ACETATE,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",5604213,C07J41/0005,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,22.0,28.6494589211277,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,"PROSTATIC NEOPLASMS, CASTRATION-RESISTANT",_NIRAPARIB,NCT03431350,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urology Centers Of Alabama, Homewood, Alabama, United States|Mayo Clinic Arizona, Phoenix, Arizona, United States|Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|The Urology Center of Colorado, Denver, Colorado, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic - Division Of Hematology/oncology, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|First Urology, PSC, Jeffersonville, Indiana, United States|Chesapeake Urology Research Associates, Towson, Maryland, United States|Massachusetts General, Boston, Massachusetts, United States|Michigan Institute of Urology, Troy, Michigan, United States|New York Oncology Hematology, Albany, New York, United States|Memorial Sloan Kettering Cancer Center, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Clinical Research Solutions, LLC, Middleburg Heights, Ohio, United States|Oregon Urology Institute, Springfield, Oregon, United States|Urologic Consultants of SE PA, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, Nashville, Tennessee, United States|Houston Metro Urology, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Saint George, Utah, United States|University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Urology of Virginia, PLCC, Virginia Beach, Virginia, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|OLV Ziekenhuis Aalst, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|ULB Hôpital Erasme, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Az Groeninge, Kortrijk, Belgium|Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Belgium|Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|University Health Network (UHN) Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centre Oscar Lambret, Lille, France|Institut Regional du Cancer de Montpellier Val d'Aurelle, Montpellier, France|Hopital Bichat Claude Bernard, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Centre Hopitalier Inter-Communal De Cornouaille, Quimper, France|Centre Eugene Marquis, Rennes Cedex, France|HIA Begin, Saint Mande, France|Clinique Sainte Anne, Strasbourg, France|Asaf Harofe Medical Center, Beer Yaakov, Israel|Soroka Hospital, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center Tel Hashomer, Ramat Gan, Israel|Azienda USL Toscana Sud Est -Ospedale di Grosseto, Arezzo, Italy|Policlinico Sant'Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Oncologia Azienda Ospedaliera ''Istituti Ospitalieri'' di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi di Firenze, Firenze, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|IRCCS-Fondazione Pascale, Napoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Vall D'Hebron, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Virgen de La Victoria, Malaga, Spain|Royal United Hospital, Bath, United Kingdom|Guy's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|The Royal Marsden NHS Trust Sutton, Sutton, United Kingdom|Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Truro, United Kingdom",8859562,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,METASTATIC PROSTATE CANCER,_PREDNISONE,NCT03764540,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada",6488960,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,METASTATIC PROSTATE CANCER,_CABAZITAXEL,NCT03764540,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada",5438072,3,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,8.0,20.2714634797429,9.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.69,835.9324,202.45,10.0,3.0,6.0,86.25,213.4,15.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,METASTATIC PROSTATE CANCER,_DOCETAXEL,NCT03764540,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada",4814470,C07D305/14,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,0.0,0.0,1.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,METASTATIC PROSTATE CANCER,_ABIRATERONE,NCT04262154,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities), Commack, New York, United States|Memoral Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States",5604213,C07J41/0005,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,CASTRATION-RESISTANT PROSTATIC CANCER,_DOCETAXEL,NCT04404140,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology, Tucson, Arizona, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|USO - Tyler Cancer Ctr, Tyler, Texas, United States|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Centre Val Aurelle Paul Lamarque; Radiotherapie, Montpellier, France|Hopital d'Instruction des Armees de Begin, Saint-Mande, France|Gustave Roussy, Villejuif CEDEX, France|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland",4814470,C07D305/14,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,OVARIAN NEOPLASMS,_NIRAPARIB,NCT03955471,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Newport Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Solvang, California, United States|GSK Investigational Site, Coral Gables, Florida, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Covington, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Burlington, Massachusetts, United States|GSK Investigational Site, Maplewood, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Harrison, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Willow Grove, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Germantown, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, The Woodlands, Texas, United States|GSK Investigational Site, Charlottesville, Virginia, United States",8859562,4,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,METASTATIC PROSTATE CANCER,_ENZALUTAMIDE,NCT04179864,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Institute of Urology - Northwest, Tucson, Arizona, United States|San Bernardino Urological Associates, San Bernardino, California, United States|The Urology Center Of Colorado, Denver, Colorado, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Norton Cancer Institute - Broadway, Louisville, Kentucky, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Oncology Consultants - Texas Medical Center, Houston, Texas, United States|Urology San Antonio, San Antonio, Texas, United States",7709517,C07D233/70,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,METASTATIC PROSTATE CANCER,_TAZEMETOSTAT,NCT04179864,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Institute of Urology - Northwest, Tucson, Arizona, United States|San Bernardino Urological Associates, San Bernardino, California, United States|The Urology Center Of Colorado, Denver, Colorado, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Norton Cancer Institute - Broadway, Louisville, Kentucky, United States|Comprehensive Cancer Centers of Nevada - Central Valley, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|Oncology Consultants - Texas Medical Center, Houston, Texas, United States|Urology San Antonio, San Antonio, Texas, United States",8410088,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,PROSTATE ADENOCARCINOMA,_ENZALUTAMIDE,NCT03829930,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"George Washington University - Medical Faculty Associates, Washington, District of Columbia, United States",7709517,C07D233/70,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0
O=P1(N(CCCl)CCCl)NCCCO1,METASTATIC RENAL CELL CARCINOMA,_CYCLOPHOSPHAMIDE,NCT02926053,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Cancer Immune Therapy Dept. of Hematology/oncology, Herlev, Denmark",3987166,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,METASTATIC RENAL CELL CARCINOMA,_FLUDARABINE,NCT02926053,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Cancer Immune Therapy Dept. of Hematology/oncology, Herlev, Denmark",7547776,C07H19/16,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_CYCLOPHOSPHAMIDE,NCT04227275,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Insitute, Nashville, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States",3987166,7,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_FLUDARABINE,NCT04227275,Phase 1,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Insitute, Nashville, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States",7547776,C07H19/16,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,"CARCINOMA, RENAL CELL",_EVEROLIMUS,NCT04195750,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama - Birmingham ( Site 1538), Birmingham, Alabama, United States|St Joseph Heritage Healthcare ( Site 1531), Santa Rosa, California, United States|University Of Colorado ( Site 1540), Aurora, Colorado, United States|UCHealth Highlands Ranch Hospital ( Site 1560), Highlands Ranch, Colorado, United States|Sibley Memorial Hospital ( Site 1559), Washington, District of Columbia, United States|Northwest Georgia Oncology Centers PC ( Site 1520), Marietta, Georgia, United States|The University of Chicago Medical Center ( Site 1539), Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514), Baltimore, Maryland, United States|Dana Farber Cancer Institute ( Site 1505), Boston, Massachusetts, United States|Henry Ford Cancer Center ( Site 1511), Detroit, Michigan, United States|Hattiesburg Clinic ( Site 1509), Hattiesburg, Mississippi, United States|St. Vincent Frontier Cancer Center ( Site 1549), Billings, Montana, United States|University of Rochester Medical Center ( Site 1543), Rochester, New York, United States|University of North Carolina at Chapel Hill ( Site 1537), Chapel Hill, North Carolina, United States|Oncology Hematology Care, Inc. ( Site 1524), Cincinnati, Ohio, United States|Cleveland Clinic ( Site 1504), Cleveland, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1523), Tulsa, Oklahoma, United States|Oregon Health & Science University ( Site 1553), Portland, Oregon, United States|Abramson Cancer Center ( Site 1525), Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center ( Site 1506), Philadelphia, Pennsylvania, United States|Medical University of South Carolina ( Site 1518), Charleston, South Carolina, United States|Henry Joyce Cancer Clinic ( Site 1544), Nashville, Tennessee, United States|Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 1653), Sao Paulo, Brazil|Sociedad de Investigaciones Medicas Limitadas ( Site 0004), Temuco, Araucania, Chile|Sociedad Medica Aren y Bachero Limitada ( Site 0003), Santiago, Region M. De Santiago, Chile|Fundacion Centro de Investigacion Clinica CIC ( Site 1703), Medellin, Antioquia, Colombia|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1709), Valledupar, Cesar, Colombia|Administradora Country SA - Clinica del Country ( Site 1701), Bogota, Distrito Capital De Bogota, Colombia|Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1702), Bogota, Distrito Capital De Bogota, Colombia|Oncologos del Occidente S.A. ( Site 1708), Pereira, Risaralda, Colombia|Masarykuv onkologicky ustav ( Site 0105), Brno, Brno-mesto, Czechia|Fakultni nemocnice Ostrava ( Site 0103), Ostrava, Moravskoslezsky Kraj, Czechia|Fakultni nemocnice Hradec Kralove ( Site 0106), Hradec Kralove, Czechia|Fakultni nemocnice Olomouc ( Site 0104), Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady ( Site 0102), Praha 10, Czechia|Herlev Hospital ( Site 0251), Herlev, Hovedstaden, Denmark|Aarhus University Hospital Skejby ( Site 0250), Aarhus, Midtjylland, Denmark|Tampereen yliopistollinen sairaala ( Site 0300), Tampere, Pirkanmaa, Finland|Kuopion Yliopistollinen Sairaala ( Site 0304), Kuopio, Pohjois-Savo, Finland|HYKS. ( Site 0302), Helsinki, Uusimaa, Finland|TYKS T-sairaala Syopatautien pkl ( Site 0301), Turku, Varsinais-Suomi, Finland|HUS Hopital Hautepierre ( Site 0350), Strasbourg, Bas-Rhin, France|Centre Francois Baclesse ( Site 0360), Caen, Calvados, France|CHU Besancon - Hopital Jean Minjoz ( Site 0351), Besancon, Doubs, France|Institut de Cancerologie du Gard - CHU Caremeau ( Site 0352), Nimes, Gard, France|Centre Hospitalier Lyon Sud ( Site 0354), Pierre Benite, Rhone, France|Gustave Roussy ( Site 0353), Villejuif, Val-de-Marne, France|Universitaetsklinikum Jena ( Site 0402), Jena, Thuringen, Germany|Prince of Wales Hospital ( Site 1050), Hong Kong, Hong Kong|Queen Mary Hospital ( Site 1051), Hong Kong, Hong Kong|Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0502), Miskolc, Borsod-Abauj-Zemplen, Hungary|Orszagos Onkologiai Intezet ( Site 0503), Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 0504), Debrecen, Hungary|Medical Oncology Ospedale San Donato ( Site 0609), Arezzo, Italy|Policlinico S. Orsola-Malpighi ( Site 0606), Bologna, Italy|Fondazione Salvatore Maugeri IRCCS ( Site 0600), Pavia, Italy|Fondazione Policlinico Universitario A. Gemelli ( Site 0607), Roma, Italy|Azienda Ospedaliera Santa Maria ( Site 0602), Terni, Italy|Azienda Ospedaliera Universitaria di Verona ( Site 0605), Verona, Italy|National Cancer Center Hospital East ( Site 1001), Kashiwa, Chiba, Japan|National Cancer Center Hospital ( Site 1003), Tokyo, Japan|Toranomon Hospital ( Site 1004), Tokyo, Japan|The Cancer Institute Hospital of JFCR ( Site 1000), Tokyo, Japan|Keio University Hospital ( Site 1002), Tokyo, Japan|National Cancer Center ( Site 1204), Gyeonggi-do, Kyonggi-do, Korea, Republic of|Chungnam National University Hospital ( Site 1205), Daejeon, Taejon-Kwangyokshi, Korea, Republic of|Korea University Anam Hospital ( Site 1203), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 1202), Seoul, Korea, Republic of|Asan Medical Center ( Site 1200), Seoul, Korea, Republic of|Samsung Medical Center ( Site 1201), Seoul, Korea, Republic of|Akershus universitetssykehus ( Site 0851), Lorenskog, Akershus, Norway|Helse Bergen HF - Haukeland Universitetssykehus ( Site 0854), Bergen, Hordaland, Norway|Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 1151), Krasnoyarsk, Krasnoyarskiy Kray, Russian Federation|SBIH City clinical hospital named after D.D. Pletniov ( Site 1160), Moscow, Moskva, Russian Federation|N.N. Blokhin NMRCO ( Site 1156), Moscow, Moskva, Russian Federation|Russian Scientific Center of Roentgenoradiology ( Site 1155), Moscow, Moskva, Russian Federation|First Moscow State Medical University n.a. I.M.Sechenov ( Site 1163), Moscow, Moskva, Russian Federation|Central Clinical Hospital with Polyclinic ( Site 1157), Moscow, Moskva, Russian Federation|Omsk Clinical Oncology Dispensary ( Site 1150), Omsk, Omskaya Oblast, Russian Federation|SBHI SPb Clinical Research Centre of specialized types of medical care ( Site 1159), Saint-Petersburg, Sankt-Peterburg, Russian Federation|City clinical oncological dispensary ( Site 1154), Sankt-Petersburg, Sankt-Peterburg, Russian Federation|Instituto Catalan de Oncologia - ICO ( Site 1251), L Hospitalet De Llobregat, Barcelona, Spain|Instituto Valenciano de Oncologia - IVO ( Site 1254), Valencia, Valenciana, Comunitat, Spain|Hospital Universitari Vall d Hebron ( Site 1250), Barcelona, Spain|Hospital Ramon y Cajal ( Site 1253), Madrid, Spain|Hospital General Universitario 12 de Octubre ( Site 1252), Madrid, Spain|National Cheng Kung University Hospital ( Site 1103), Tainan, Taiwan|National Taiwan University Hospital ( Site 1100), Taipei, Taiwan|Taipei Veterans General Hospital ( Site 1101), Taipei, Taiwan|Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1302), Edirne, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1305), Istanbul, Turkey|Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi ( Site 1303), Istanbul, Turkey|MI Dnipr Regional Clinical Hospital named after I.I. Mechnikov ( Site 1453), Dnipropetrovsk, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 1452), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|Kyiv City Clinical Oncology Center ( Site 1450), Kyiv, Kyivska Oblast, Ukraine|Western General Hospital ( Site 1400), Edinburgh, Edinburgh, City Of, United Kingdom",5665772,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,BLADDER CANCER,_GEMCITABINE,NCT02885974,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor Clinic, Houston, Texas, United States|Harris Health System - Smith Clinic, Houston, Texas, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,BLADDER CANCER,_CELECOXIB,NCT02885974,Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor Clinic, Houston, Texas, United States|Harris Health System - Smith Clinic, Houston, Texas, United States",5972986.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,BLADDER CANCER,_PACLITAXEL,NCT04060459,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PROSTATE CANCER METASTATIC,_OLAPARIB,NCT03434158,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|ICO L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitario i Politècnic La Fe, Valencia, Spain",7151102,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,PROSTATE CANCER RECURRENT,_HYDROXYCHLOROQUINE,NCT04011410,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Markey Cancer Center - University of Kentucky, Lexington, Kentucky, United States",4181725,2,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,PROSTATE CANCER RECURRENT,_HYDROXYCHLOROQUINE_SULFATE,NCT04011410,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Markey Cancer Center - University of Kentucky, Lexington, Kentucky, United States",5318960,A61K47/44,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,26.0,24.1154849175547,142.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(C)NCC(O)COc1cccc2ccccc12,POSTPARTUM HAEMORRHAGE,_PROPRANOLOL,NCT03434444,Not Applicable,Recruiting,Female,"16 Years to 40 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mount Sinai Hospital, Toronto, Ontario, Canada",6500454,1,0.0,1.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
C[N+](C)(C)CCO,PROSTATE ADENOCARCINOMA,_CHOLINE,NCT03404648,Phase 3,Enrolling by invitation,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.6,104.1708,20.23,1.0,1.0,0.0,12.57,42.19,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=C([O-])C[N+]12CC[N+]3(CC(=O)[O-])CC[N+]4([C@@H](CO)[C@@H](O)CO)CC[N+](CC(=O)[O-])(CC1)[Gd-]234,PROSTATE ADENOCARCINOMA,_GADOBUTROL,NCT03404648,Phase 3,Enrolling by invitation,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States",5980864,C07D257/02,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,103.722869052752,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.35,604.72,181.08,9.0,3.0,4.0,45.39,143.47,10.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,BLADDER CANCER,_ASCORBIC_ACID,NCT04046094,Phase 1|Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Kansas Cancer Center (KUCC), Fairway, Kansas, United States|The University of Kansas Medical Center, Kansas City, Kansas, United States|The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States",7169381.0,7,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,KIDNEY CANCER,_PAZOPANIB,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",7105530,C07D231/56,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,KIDNEY CANCER,_SUNITINIB,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,KIDNEY CANCER,_TEMSIROLIMUS,NCT03571438,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grenoble Alps Hospital, Grenoble, France",5362718,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,RENAL CELL CARCINOMA,_SUNITINIB,NCT02919371,Phase 1|Phase 2,Recruiting,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia",6573293,C07D403/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,EFFICACY AND SAFETY,_VITAMIN_A,NCT03779776,Not Applicable,Recruiting,All,up to 96 Hours   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Zhengzhou Children's Hospital, Zhengzhou, Henan, China",3932634.0,0,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,3344.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,6.38,286.4516,20.23,1.0,1.0,1.0,36.54,97.92,5.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,ERECTILE DYSFUNCTION|PROSTATE CANCER,_PENTOXIFYLLINE,NCT03406169,Phase 3,Recruiting,Male,"30 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Brooke Army Medical Center, San Antonio, Texas, United States",4189469,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,ERECTILE DYSFUNCTION|PROSTATE CANCER,_SILDENAFIL,NCT03406169,Phase 3,Recruiting,Male,"30 Years to 89 Years   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Brooke Army Medical Center, San Antonio, Texas, United States",5250534.0,C07D487/04,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,METASTATIC RENAL CELL CARCINOMA,_CABOZANTINIB,NCT03149822,Phase 1|Phase 2,Recruiting,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Aurora, Colorado, United States|Memorial Hospital Central, Colorado Springs, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Highlands Ranch Hospital, Highlands Ranch, Colorado, United States|UCHealth Lone Tree Medical Center, Lone Tree, Colorado, United States",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,"CARCINOMA, RENAL CELL",_CABOZANTINIB,NCT04338269,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates, Flagstaff, Arizona, United States|University of Arizona, Tucson, Arizona, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|UC San Diego Health System, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California Davis, Sacramento, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|Highlands Ranch Hospital, Highlands Ranch, Colorado, United States|Rocky Mountain Cancer Center - Denver, Littleton, Colorado, United States|Hartford Healthcare, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Woodlands Medical Specialists, P.A., Pensacola, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Skip Viragh Outpatient Cancer Building, Baltimore, Maryland, United States|MGH, Boston, Massachusetts, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|New York Oncology Hematology,P.C.-Albany, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center - Commack, Commack, New York, United States|MSKCC @ West Harrison, Harrison, New York, United States|New York University, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology - Houston (Gessner), Houston, Texas, United States|Texas Oncology - Willowbrook, Houston, Texas, United States|University Of Utah, Salt Lake City, Utah, United States|Virginia Cancer Specialists - Gainsville, Gainesville, Virginia, United States|University of Wisconsin, Madison, Wisconsin, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Centro Medico Austral OMI, Ciudad Autonoma Buenos Aires, Argentina|Orange Hospital, Orange, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Bendigo Cancer Centre, Bendigo, Victoria, Australia|Box Hill Hospital; Oncology, Box Hill, Victoria, Australia|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France|CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux, France|Centre Francois Baclesse; Oncologie, Caen, France|Centre Jean Perrin; Oncologie, Clermont Ferrand, France|Centre Oscar Lambret; Chir Cancerologie General, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Institut de cancerologie du Gard, Nimes, France|Hopital Hautepierre; Hematologie Oncologie, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Oncologie Medicale, Villejuif, France|Zeisigwaldkliniken Bethanien, Chemnitz, Germany|Klinikum der Johann Wolfgang Goethe-Universitaet; Urologie und Kinderurologie, Frankfurt, Germany|Universitaetsklinikum Freiburg; Urology, Freiburg, Germany|Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie, Halle (Saale), Germany|Uniklinik-Eppendorf; Klinik U Poliklinik F Urologie, Hamburg, Germany|Med. Hochschule Hannover, Hämatologie, Hämostaseologie, Onkologie u. Stammzelltransplantation, Hannover, Germany|Universitaetsklinikum Muenster; Urology, Muenster, Germany|Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München, Germany|Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen, Germany|Universitätsklinikum Ulm; Klinik für Urologie, Ulm, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, Greece|Attikon University General Hospital, Athens, Greece|Athens Medical Center; Dept. of Oncology, Athens, Greece|University Hospital of Larissa;Department of Medical Oncology, Larissa, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Diavalkaniko Hospital, Thessaloniki, Greece|Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); SOC Oncologia Medica A, Aviano (PN), Friuli-Venezia Giulia, Italy|Policlinico Universitario ""Agostino Gemelli""; U.O.C. Oncologia Medica, Roma, Lazio, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Fondazione Salvatore Maugeri; Divisione Di Oncologia Medica, Pavia, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Ospedale Di Macerata; Oncologia, Macerata, Marche, Italy|Fondazione del Piemonte per l'Oncologia (IRCCS); Day Hospital Oncologico Multidisciplinare, Candiolo (TO), Piemonte, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|Kyushu University Hospital, Fukuoka, Japan|Hokkaido University Hospital, Hokkaido, Japan|University of Tsukuba Hospital, Ibaraki, Japan|Yokohama City University Hospital, Kanagawa, Japan|Okayama University Hospital, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Kindai University Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Keio University Hospital, Tokyo, Japan|Tokyo Women's Medical University Hospital, Tokyo, Japan|Chungnam National University Hospital, Daejeon, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii, Bydgoszcz, Poland|SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej, Bytom, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland|Wojewódzki Szpital Zespolony im.L.Rydygiera; Oddzial Chemioterapii Nowotworów, Toruń, Poland|Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., Warszawa, Poland|Wojskowy Instytut Medyczny; Klinika Onkologii, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wrocław, Poland|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|TSBHI Altai Territorial oncological dispensary, Barnaul, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation|Medical Center Avicenna; Urology, Novosibirsk, Russian Federation|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Alvaro Cunqueiro; Servicio de Oncologia, Vigo, Pontevedra, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Universitario de Burgos; Oncología, Burgos, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|Royal Blackburn Hospital, Blackburn, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|Royal Marsden Hospital; Dept of Med-Onc, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|ROYAL MARSDEN HOSPITAL; DEPT OF MEDICAL ONCOLOGY; The Bob Champion Unit, Sutton, United Kingdom",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,0.0,0.0,0.0,1.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC,BLADDER CANCER,_CABOZANTINIB,NCT04289779,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States",7579473,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,7.0,5.9138791350951685,14.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.01,501.514,98.78,5.0,2.0,5.0,51.49,136.12,8.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1,BLADDER CANCER,_ABEMACICLIB,NCT03837821,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medicine, New York, New York, United States",7855211,C07D401/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,23.0,12.189161995112801,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.25,506.606,75.0,7.0,1.0,5.0,54.75,141.26,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,METASTATIC RENAL CELL CARCINOMA,_DECITABINE,NCT04049344,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China",5654333,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,BLADDER CANCER,_PIOGLITAZONE,NCT01935466,,Recruiting,Male,"50 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Retrospective,"Deptt of Endocrinology, Chandigarh, India",4687777,C07D213/30,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0
NC[C@H]1CC[C@H](C(=O)O)CC1,BLADDER CANCER,_TRANEXAMIC_ACID,NCT01869413,Phase 2|Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Northern Alberta Urology Centre, Edmonton, Alberta, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|London Health Sciences Complex (LHSC), London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Montréal, Quebec, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada|Centre Hospitalier de l'Université de Québec (CHUQ), Québec, Canada",8273795.0,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
FC(F)(F)C(F)(F)C(F)(F)F,KIDNEY CANCER,_PERFLUTREN,NCT04021238,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",6723303,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0
FS(F)(F)(F)(F)F,KIDNEY CANCER,_SULFUR_HEXAFLUORIDE,NCT04021238,Phase 2,Recruiting,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States",5686060,A61K49/223,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,11.0,31.0150105751658,3.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.28,146.05,0.0,0.0,0.0,0.0,7.11,18.44,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,OVERACTIVE BLADDER|PARKINSON DISEASE,_SOLIFENACIN,NCT03149809,Phase 3,Recruiting,All,"Child, Adult, Older Adult",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States|Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia, United States|Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States|Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States",6017927,C07D453/02,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,7.0,28.9122979937986,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.9,362.473,32.78,2.0,0.0,5.0,40.13,106.06,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
N[C@]1(C(=O)O)C[C@@H](F)C1,PROSTATE CANCER,_FLUCICLOVINE,NCT04009083,Not Applicable,Recruiting,Male,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"NYU Langone Health, New York, New York, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.0,133.122,63.32,3.0,2.0,1.0,11.65,27.75,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
N[C@]1(C(=O)O)C[C@@H](F)C1,PROSTATE ADENOCARCINOMA,_FLUCICLOVINE,NCT03762759,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grady Health System, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-3.0,133.122,63.32,3.0,2.0,1.0,11.65,27.75,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@]1([18F])C[C@@](N)(C(=O)O)C1,PROSTATE ADENOCARCINOMA,_FLUCICLOVINE_F18,NCT03762759,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Grady Health System, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,URINARY RETENTION,_TAMSULOSIN,NCT03609580,Phase 1|Phase 2,Recruiting,Male,65 Years and older   (Older Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HackensackUMC, Hackensack, New Jersey, United States",4703063,C07D203/10,0.0,0.0,1.0,0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,27.3024086736894,325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.05,408.51199999999994,99.88,6.0,2.0,2.0,43.95,108.86,11.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
O=[N+]([O-])[O-],ERECTILE DYSFUNCTION,_NITRATE,NCT04116060,Not Applicable,Recruiting,Male,"40 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University Hospital Essen, Essen, NRW, Germany",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.84,62.0049,66.2,3.0,0.0,0.0,3.28,8.35,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(=O)C(=O)O,PROSTATE ADENOCARCINOMA,_PYRUVATE,NCT03933670,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, San Francisco, San Francisco, California, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_AFURESERTIB,NCT04060394,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Urological Associates of Southern Arizona, Tucson, Arizona, United States|California Cancer Associates for Researh & Excellence, Inc, Encinitas, California, United States|Eastern Connnecticut Hematology/Oncology Associates, Norwich, Connecticut, United States|Associated Medical Professionals of NY, Syracuse, New York, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States",US-20090209607-A1,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,66.0,55.5904638698946,11.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.45,427.32,72.94,3.0,2.0,3.0,40.89,116.81,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0
O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,BLADDER CANCER,_GENISTEIN,NCT01489813,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Department of Urology, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",5213971,C12N15/76,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,4.0,20.8957062773362,2541.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.04,270.2369,86.99,5.0,3.0,3.0,26.59,71.68,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_DAROLUTAMIDE,NCT04237584,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Myrtle Beach, South Carolina, United States",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,52.403540113760045,4.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,398.85,119.62,5.0,3.0,3.0,41.86,117.16,6.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,IDIOPATHIC MEMBRANOUS NEPHROPATHY,_PREDNISONE,NCT03549663,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Xinhua Hospital affliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, Shanghai, China",6488960,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,IDIOPATHIC MEMBRANOUS NEPHROPATHY,_TACROLIMUS,NCT03549663,Not Applicable,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Xinhua Hospital affliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, Shanghai, China",5260301,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,PROSTATE CANCER,_VALACYCLOVIR,NCT01436968,Phase 3,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Arizona Oncology Services Foundation, Multiple Locations, Arizona, United States|Southern Arizona VA Health Care System, Tucson, Arizona, United States|VA Northern California Health Care System, Mather, California, United States|Precision Radiation Oncology, Tustin, California, United States|Valley View Hospital, Glenwood Springs, Colorado, United States|Colorado Clinical Research, Golden, Colorado, United States|Advanced Urology, Parker, Colorado, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|21st Century Oncology, Fort Lauderdale, Florida, United States|21st Century Oncology, Lakewood Ranch, Florida, United States|21st Century Oncology, Naples, Florida, United States|21st Century Oncology, Plantation, Florida, United States|Clinical Research Center of Florida, Pompano Beach, Florida, United States|James A. Haley Veteran's Hospital, Tampa, Florida, United States|Florida Urology Partners, Tampa, Florida, United States|Atlanta VA Health Care System, Decatur, Georgia, United States|Jesse Brown VA Medical Center, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|Silver Cross Hospital, New Lenox, Illinois, United States|Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, United States|VA Maryland Health Care System, Baltimore, Maryland, United States|Chesapeake Urology Research Associates, Baltimore, Maryland, United States|The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Kansas City VA Medical Center, Kansas City, Missouri, United States|Adult & Pediatric Urology, P.C., Omaha, Nebraska, United States|Sheldon Freedman MD, Ltd., Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|New Jersey Urology - Cherry Hill, Cherry Hill, New Jersey, United States|New Jersey Urology - Englewood, Englewood, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|New Jersey Urology - Milburn, Millburn, New Jersey, United States|New Jersey Urology - Saddle Brook, Saddle Brook, New Jersey, United States|New Jersey Urology - Voorhees, Voorhees, New Jersey, United States|New Jersey Urology - West Orange, West Orange, New Jersey, United States|New Mexico Oncology Hematology Consultants (NMOHC), Albuquerque, New Mexico, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|James J. Peters VA Medical Center, Bronx, New York, United States|Advanced Radiation Centers of New York (Integrated Medical Professionals), North Hills, New York, United States|Associated Medical Professionals of NY, PLLC, Syracuse, New York, United States|Durham VA Health Care System, Durham, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, Ohio, United States|Southwest Urology, Clinical Research Solutions, Middleburg Heights, Ohio, United States|VA Portland Health Care System, Portland, Oregon, United States|Oregon Urology Institute, Springfield, Oregon, United States|MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States|Lancaster Urology, Lancaster, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Triangle Urological Group, Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Wexford Health and Wellness Pavilion, Cancer Institute, Wexford, Pennsylvania, United States|Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina, United States|Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina, United States|Austin Urology Institute, Austin, Texas, United States|VA North Texas Health Care System, Dallas, Texas, United States|Urology Clinics of North Texas, Dallas, Texas, United States|Dr. Irving Fishman's Office, Houston, Texas, United States|Houston Willowbrook Radiation Oncology, Houston, Texas, United States|Dr. Ned Stein's Office, Houston, Texas, United States|South Texas San Antonio VA Healthcare System, San Antonio, Texas, United States|The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Texas Urology Specialists-The Woodlands, The Woodlands, Texas, United States|The Methodist Hospital - The Woodlands, The Woodlands, Texas, United States|Texas Urology Specialists, Tomball, Texas, United States|Potomac Urology Center, Alexandria, Virginia, United States|Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States|Salem VA Medical Center, Salem, Virginia, United States|Urology of Virginia, PLLC, Virginia Beach, Virginia, United States|MultiCare Regional Cancer Center - Gig Harbor, Gig Harbor, Washington, United States|MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, United States|VA Caribbean Healthcare System, San Juan, Puerto Rico",4957924,C07D473/00,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,24.0,25.4625351649931,393.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.84,324.3357,146.85,8.0,3.0,2.0,31.96,80.63,8.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,"POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT",_TOLVAPTAN,NCT02847624,,Recruiting,All,"Child, Adult, Older Adult",Industry,Observational Model: Cohort|Time Perspective: Prospective,"Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan",5753677,5,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
N[C@@H](Cc1c[nH]cn1)C(=O)O,"RENAL INSUFFICIENCY, CHRONIC",_HISTIDINE,NCT02947750,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Atlanta VA Health Care System, Decatur, Georgia, United States",3943038.0,C12N1/38,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,9.0,18.858703464136802,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.7,155.1546,92.0,4.0,3.0,1.0,14.67,38.06,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,"RENAL INSUFFICIENCY, CHRONIC",_FOLIC_ACID,NCT02947750,Phase 2,Recruiting,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Atlanta VA Health Care System, Decatur, Georgia, United States",3960757.0,A61K9/1694,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CN(C)C(=N)NC(=N)N,"RENAL INSUFFICIENCY, CHRONIC",_METFORMIN,NCT02895750,Phase 2,Recruiting,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU Amiens Picardie, Amiens, France",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O,ACUTE KIDNEY INJURY,_FRUCTOSE,NCT04310514,Not Applicable,Recruiting,All,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,"Medical University of Gdansk, Gdańsk, Poland",WO-2006138705-A1,A23L7/1963 ,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.4,180.1559,110.38,6.0,5.0,1.0,16.29,36.36,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,_PRAVASTATIN,NCT04284657,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Keck School of Medicine of University of Southern California, Los Angeles, California, United States",5622985.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Na+].[Na+].[Na+],AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,_SODIUM_CITRATE,NCT04284657,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Keck School of Medicine of University of Southern California, Los Angeles, California, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-0.55,258.068,140.62,7.0,1.0,0.0,14.23,68.14,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,FOCAL SEGMENTAL GLOMERULOSCLEROSIS,_IRBESARTAN,NCT03493685,Phase 3,Recruiting,All,"8 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Retrophin Investigational Site, Florence, Alabama, United States|Retrophin Investigational Site, Homewood, Alabama, United States|Retrophin Investigational Site, Mesa, Arizona, United States|Retrophin Investigational Site, Phoenix, Arizona, United States|Retrophin Investigational Site, Los Angeles, California, United States|Retrophin Investigational Site, Northridge, California, United States|Retrophin Investigational Site, Palo Alto, California, United States|Retrophin Investigational Site, San Diego, California, United States|Retrophin Investigational Site, San Dimas, California, United States|Retrophin Investigational Site, San Francisco, California, United States|Retrophin Investigational Site, Santa Clarita, California, United States|Retrophin Investigational Site, Torrance, California, United States|Retrophin Investigational Site, Victorville, California, United States|Retrophin Investigational Site, Whittier, California, United States|Retrophin Investigational Site, Aurora, Colorado, United States|Retrophin Investigational Site, Denver, Colorado, United States|Retrophin Investigational Site, Denver, Colorado, United States|Retrophin Investigational Site, Norwich, Connecticut, United States|Retrophin Investigational Site, Wilmington, Delaware, United States|Retrophin Investigational Site, Washington, District of Columbia, United States|Retrophin Investigational Site, Coral Springs, Florida, United States|Retrophin Investigational Site, Fort Lauderdale, Florida, United States|Retrophin Investigational Site, Miami, Florida, United States|Retrophin Investigational Site, Miami, Florida, United States|Retrophin Investigational Site, Miami, Florida, United States|Retrophin Investigational Site, Ocala, Florida, United States|Retrophin Investigational Site, Orlando, Florida, United States|Retrophin Investigational Site, Port Charlotte, Florida, United States|Retrophin Investigational Site, Tampa, Florida, United States|Retrophin Investigational Site, Temple Terrace, Florida, United States|Retrophin Investigational Site, Winter Park, Florida, United States|Retrophin Investigational Site, Atlanta, Georgia, United States|Retrophin Investigational Site, Columbus, Georgia, United States|Retrophin Investigational Site, Lawrenceville, Georgia, United States|Meridian ID, Meridian, Idaho, United States|Retrophin Investigational Site, Chicago, Illinois, United States|Retrophin Investigational Site, Merrillville, Indiana, United States|Retrophin Investigational Site, Iowa City, Iowa, United States|Retrophin Investigational Site, Kansas City, Kansas, United States|Retrophin Investigational Site, Wichita, Kansas, United States|Retrophin Investigational Site, Louisville, Kentucky, United States|Retrophin Investigational Site, Monroe, Louisiana, United States|Retrophin Investigational Site, New Orleans, Louisiana, United States|Retrophin Investigational Site, Shreveport, Louisiana, United States|Retrophin Investigational Site, Portland, Maine, United States|Retrophin Investigational Site, Baltimore, Maryland, United States|Retrophin Investigational Site, Boston, Massachusetts, United States|Retrophin Investigational Site, Boston, Massachusetts, United States|Retrophin Investigational Site, Springfield, Massachusetts, United States|Retrophin Investigational Site, Ann Arbor, Michigan, United States|Retrophin Investigational Site, Minneapolis, Minnesota, United States|Retrophin Investigational Site, Minneapolis, Minnesota, United States|Retrophin Investigational Site, Kansas City, Missouri, United States|Retrophin Investigational Site, Kansas City, Missouri, United States|Retrophin Investigational Site, Saint Louis, Missouri, United States|Retrophin Investigational Site, Lincoln, Nebraska, United States|Retrophin Investigational Site, Las Vegas, Nevada, United States|Retrophin Investigational Site, Reno, Nevada, United States|Retrophin Investigational Site, Hackensack, New Jersey, United States|Retrophin Investigational Site, Bronx, New York, United States|Retrophin Investigational Site, Flushing, New York, United States|Retrophin Investigational Site, New Hyde Park, New York, United States|Retrophin Investigational Site, New York, New York, United States|Retrophin Investigational Site, New York, New York, United States|Retrophin Investigational Site, New York, New York, United States|Retrophin Investigational Site, Stony Brook, New York, United States|Retrophin Investigational Site, Chapel Hill, North Carolina, United States|Retrophin Investigational Site, Greenville, North Carolina, United States|Retrophin Investigational Site, Raleigh, North Carolina, United States|Retrophin Investigational Site, Winston-Salem, North Carolina, United States|Retrophin Investigational Site, Akron, Ohio, United States|Retrophin Investigational Site, Cleveland, Ohio, United States|Retrophin Investigational Site, Columbus, Ohio, United States|Retrophin Investigational Site, Oklahoma City, Oklahoma, United States|Retrophin Investigational Site, Bend, Oregon, United States|Retrophin Investigational Site, Roseburg, Oregon, United States|Retrophin Investigational Site, Bethlehem, Pennsylvania, United States|Retrophin Investigational Site, Camp Hill, Pennsylvania, United States|Retrophin Investigational Site, Philadelphia, Pennsylvania, United States|Retrophin Investigational Site, Upland, Pennsylvania, United States|Retrophin Investigational Site, Columbia, South Carolina, United States|Retrophin Investigational Site, Memphis, Tennessee, United States|Retrophin Investigational Site, Nashville, Tennessee, United States|Retrophin Investigational Site, Amarillo, Texas, United States|Retrophin Investigational Site, Corpus Christi, Texas, United States|Retrophin Investigational Site, Dallas, Texas, United States|Retrophin Investigational Site, Dallas, Texas, United States|Retrophin Investigational Site, Dallas, Texas, United States|Retrophin Investigational Site, El Paso, Texas, United States|Retrophin Investigational Site, Fort Worth, Texas, United States|Retrophin Investigational Site, Houston, Texas, United States|Retrophin Investigational Site, Houston, Texas, United States|Retrophin Investigational Site, Lewisville, Texas, United States|Retrophin Investigational Site, Sherman, Texas, United States|Retrophin Investigational Site, Webster, Texas, United States|Retrophin Investigational Site, Saint George, Utah, United States|Retrophin Investigational Site, Salt Lake City, Utah, United States|Retrophin Investigational Site, Salt Lake City, Utah, United States|Retrophin Investigational Site, Alexandria, Virginia, United States|Retrophin Investigational Site, Fairfax, Virginia, United States|Retrophin Investigational Site, Hampton, Virginia, United States|Retrophin Investigational SIte, Lansdowne Town Center, Virginia, United States|Retrophin Investigational Site, Norfolk, Virginia, United States|Retrophin Investigational Site, Spokane, Washington, United States|Retrophin Investigational Site, Tacoma, Washington, United States|Retrophin Investigational Site, Morgantown, West Virginia, United States|Retrophin Investigational Site, Marshfield, Wisconsin, United States|Retrophin Investigational Site, Milwaukee, Wisconsin, United States|Retrophin Investigational Site, Wauwatosa, Wisconsin, United States|Retrophin Investigational Site, Buenos Aires, Argentina|Retrophin Investigational Site, Córdoba, Argentina|Retrophin Investigational Site, Santa Fe, Argentina|Retrophin Investigational Site, Concord, New South Wales, Australia|Retrophin Investigational Site, New Lambton, New South Wales, Australia|Retrophin Investigational Site, Saint Leonards, New South Wales, Australia|Retrophin Investigational Site, Wollongong, New South Wales, Australia|Retrophin Investigational Site, Birtinya, Queensland, Australia|Retrophin Investigational Site, Woolloongabba, Queensland, Australia|Retrophin Investigational Site, Adelaide, South Australia, Australia|Retrophin Investigational Site, Parkville, Victoria, Australia|Retrophin Investigational Site, Nedlands, Western Australia, Australia|Retrophin Investigational Site, Bruxelles, Belgium|Retrophin Investigational Site, Kortrijk, Belgium|Retrophin Investigational Site, Leuven, Belgium|Retrophin Investigational Site, Liège, Belgium|Retrophin Investigational Site, Roeselare, Belgium|Retrophin Investigational Site, Botucatu, Brazil|Retrophin Investigational Site, Itaquera, Brazil|Retrophin Investigational Site, Porto Alegre, Brazil|Retrophin Investigational Site, São Paulo, Brazil|Retrophin Investigational Site, São Paulo, Brazil|Retrophin Investigational Site, Edmonton, Alberta, Canada|Retrophin Investigational Site, London, Ontario, Canada|Retrophin Investigational Site, Greenfield Park, Quebec, Canada|Retrophin Investigational Site, Montréal, Quebec, Canada|Retrophin Investigational Site, Montréal, Quebec, Canada|Retrophin Investigational Site, Osijek, Croatia|Retrophin Investigational Site, Zagreb, Croatia|Retrophin Investigational Site, Praha 10, Praha, Czechia|Retrophin Investigational Site, Praha 2, Praha, Czechia|Retrophin Investigational Site, Nový Jičín, Czechia|Retrophin Investigational Site, Aarhus, Region Midtjylland, Denmark|Retrophin Investigational Site, Kolding, Southern Denmark, Denmark|Retrophin Investigational Site, Tallinn, Estonia|Retrophin Investigational Site, Tallin, Estonia|Retrophin Investigational Site, Tartu, Estonia|Retrophin Investigational Site, Amiens, France|Retrophin Investigational Site, Bordeaux, France|Retrophin Investigational Site, Brest, France|Retrophin Investigational Site, Clermont-Ferrand, France|Retrophin Investigational Site, Créteil, France|Retrophin Investigational Site, Grenoble Cedex 9, France|Retrophin Investigational Site, Le Kremlin-Bicêtre cedex, France|Retrophin Investigational Site, Le Kremlin-Bicêtre, France|Retrophin Investigational Site, Lille, France|Retrophin Investigational Site, Marseille, France|Retrophin Investigational Site, Nice, France|Retrophin Investigational Site, Paris Cedex 15, France|Retrophin Investigational Site, Paris cedex 15, France|Retrophin Investigational Site, Paris, France|Retrophin Investigational Site, Paris, France|Retrophin Investigational Site, Saint-Priest-en-Jarez, France|Retrophin Investigational Site, Strasbourg, France|Retrophin Investigational Site, Toulouse, France|Retrophin Investigational Site, Valenciennes, France|Retrophin Investigational Site, Düsseldorf, Westfalen, Germany|Retrophin Investigational Site, Aachen, Germany|Retrophin Investigational Site, Berlin, Germany|Retrophin Investigational Site, Heidelberg, Germany|Retrophin Investigational Site, Stuttgart, Germany|Retrophin Investigational Site, Villingen-Schwenningen, Germany|Retrophin Investigational Site, Hong Kong, Hong Kong|Retrophin Investigational Site, Baja, Hungary|Retrophin Investigational Site, Bari, Italy|Retrophin Investigational Site, Bergamo, Italy|Retrophin Investigational Site, Firenze, Italy|Retrophin Investigational Site, Genova, Italy|Retrophin Investigational Site, Lecco, Italy|Retrophin Investigational Site, Milano, Italy|Retrophin Investigational Site, Monza, Italy|Retrophin Investigational Site, Pavia, Italy|Retrophin Investigational Site, Roma, Italy|Retrophin Investigational Site, Verona, Italy|Retrophin Investigational Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Retrophin Investigational Site, Busan, Korea, Republic of|Retrophin Investigational Site, Daejeon, Korea, Republic of|Retrophin Investigational Site, Gyeonggi-do, Korea, Republic of|Retrophin Investigational Site, Gyeonggi-do, Korea, Republic of|Retrophin Investigational Site, Seoul, Korea, Republic of|Retrophin Investigational Site, Seoul, Korea, Republic of|Retrophin Investigational Site, Seoul, Korea, Republic of|Retrophin Investigational Site, Auckland, New Zealand|Retrophin Investigational Site, Hamilton, New Zealand|Retrophin Investigational Site, Olsztyn, Poland|Retrophin Investigational Site, Olsztyn, Poland|Retrophin Investigational Site, Piotrków Trybunalski, Poland|Retrophin Investigational Site, Warsaw, Poland|Retrophin Investigational Site, Warsaw, Poland|Retrophin Investigational Site, Wrocław, Poland|Retrophin Investigational Site, Wrocław, Poland|Retrophin Investigational Site, Łódź, Poland|Retrophin Investigational Site, Amadora, Portugal|Retrophin Investigational Site, Carnaxide, Portugal|Retrophin Investigational Site, Coimbra, Portugal|Retrophin Investigational Site, Lisboa, Portugal|Retrophin Investigational Site, Lisbon, Portugal|Retrophin Investigational Site, Loures, Portugal|Retrophin Investigational Site, Porto, Portugal|Retrophin Investigational Site, Setúbal, Portugal|Retrophin Investigational Site, Vila Nova De Gaia, Portugal|Retrophin Investigational Site, Palma De Mallorca, Baleares, Spain|Retrophin Investigational Site, Lugo, Burela, Spain|Retrophin Investigational Site, Sagunto, Valencia, Spain|Retrophin Investigational Site, Badalona, Spain|Retrophin Investigational Site, Barcelona, Spain|Retrophin Investigational Site, Barcelona, Spain|Retrophin Investigational Site, Barcelona, Spain|Retrophin Investigational Site, Barcelona, Spain|Retrophin Investigational Site, Ciudad Real, Spain|Retrophin Investigational Site, Córdoba, Spain|Retrophin Investigational Site, Madrid, Spain|Retrophin Investigational Site, Madrid, Spain|Retrophin Investigational Site, Majadahonda, Spain|Retrophin Investigational Site, Málaga, Spain|Retrophin Investigational Site, Sevilla, Spain|Retrophin Investigational Site, Sevilla, Spain|Retrophin Investigational Site, Valencia, Spain|Retrophin Investigational Site, Valencia, Spain|Retrophin Investigational Site, Zaragoza, Spain|Retrophin Investigational Site, Göteborg, Sweden|Retrophin Investigational Site, Solna, Sweden|Retrophin Investigational Site, Uppsala, Sweden|Retrophin Investigational Site, Hualien City, Taiwan|Retrophin Investigational Site, Kaohsiung City, Taiwan|Retrophin Investigational Site, Kaohsiung, Taiwan|Retrophin Investigational Site, New Taipei City, Taiwan|Retrophin Investigational Site, Taichung, Taiwan|Retrophin Investigational Site, Taichung, Taiwan|Retrophin Investigational Site, Tainan City, Taiwan|Retrophin Investigational Site, Taipei City, Taiwan|Retrophin Investigational Site, Taipei City, Taiwan|Retrophin Investigational Site, Taipei, Taiwan|Retrophin Investigational Site, Taoyuan, Taiwan|Retrophin Investigational Site, Brighton, East Sussex, United Kingdom|Retrophin Investigational Site, Manchester, Greater Manchester, United Kingdom|Retrophin Investigational Site, Leicester, Leicestershire, United Kingdom|Retrophin Investigational Site, Carshalton, London, United Kingdom|Retrophin Investigational Site, Hampstead, London, United Kingdom|Retrophin Investigational Site, Whitechapel, London, United Kingdom|Retrophin Investigational Site, Fulwood, Preston, United Kingdom|Retrophin Investigational Site, Brighton, United Kingdom|Retrophin Investigational Site, Cambridge, United Kingdom|Retrophin Investigational Site, Cardiff, United Kingdom|Retrophin Investigational Site, Glasgow, United Kingdom|Retrophin Investigational Site, Leicester, United Kingdom|Retrophin Investigational Site, London, United Kingdom|Retrophin Investigational Site, London, United Kingdom|Retrophin Investigational Site, London, United Kingdom|Retrophin Investigational Site, Manchester, United Kingdom|Retrophin Investigational Site, Newcastle, United Kingdom|Retrophin Investigational Site, Reading, United Kingdom|Retrophin Investigational Site, Salford, United Kingdom|Retrophin Investigational Site, Swansea, United Kingdom|Retrophin Investigational Site, York, United Kingdom",5270317,C07D231/12,1.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0
[C-]#[O+],ACUTE RESPIRATORY DISTRESS SYNDROME,_CARBON_MONOXIDE,NCT03799874,Phase 2,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,BRONCHOPULMONARY DYSPLASIA,_SILDENAFIL,NCT03142568,Phase 2,Recruiting,All,up to 28 Days   (Child),Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Children's Hospital of Nevada at UMC, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Kings County Hospital Center, Brooklyn, New York, United States|Cohen Children's Medical Center of NY, New Hyde Park, New York, United States|Golisano Children's Hospital - University of Rochester Medical Center, Rochester, New York, United States|WakeMed Health and Hospitals, Raleigh, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States",5250534.0,C07D487/04,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,474.576,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,PREMATURE BIRTH,_BETAMETHASONE,NCT02469519,Phase 2|Phase 3,Recruiting,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of South Alabama Medical Center, Mobile, Alabama, United States|Phoenix Perinatal Associates, Phoenix, Arizona, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Good Samaritan Hospital, San Jose, California, United States|Presbyterian/St Luke's Hospital, Denver, Colorado, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Lousiana State University Health Science, Shreveport, Louisiana, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Harris Methodist Hospital - Fort Worth, Fort Worth, Texas, United States|Swedish Medical Center, Seattle, Washington, United States",6126920.0,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,PROSTATE CANCER METASTATIC,_RUCAPARIB,NCT03413995,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital, Baltimore, Maryland, United States",6495541,2,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,"RESPIRATORY DISTRESS SYNDROME, ADULT",_ILOPROST,NCT03111212,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital Tuebingen, Tuebingen, Germany",EP-1089970-B1,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,OVARIAN CANCER,_FOSTAMATINIB,NCT03246074,Phase 1,Recruiting,Female,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",7449458,6,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,13.0,33.7419659541263,14.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.78,580.4595,186.72,13.0,4.0,4.0,54.48,137.1,10.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,"INFERTILITY, FEMALE",_PROGESTERONE,NCT04259996,,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Observational Model: Cohort|Time Perspective: Prospective,"Instituto Valenciano de Infertilidad Spain, Valencia, Spain",5543150.0,5,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,"INFERTILITY, FEMALE",_ESTRADIOL,NCT04259996,,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Observational Model: Cohort|Time Perspective: Prospective,"Instituto Valenciano de Infertilidad Spain, Valencia, Spain",5223261,5,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,KIDNEY FAILURE,_TACROLIMUS,NCT04258423,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Indiana University, Indianapolis, Indiana, United States",5260301,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,KIDNEY FAILURE,_EVEROLIMUS,NCT04258423,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Indiana University, Indianapolis, Indiana, United States",5665772,C07D498/18,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,PROSTATE,_OLAPARIB,NCT03047135,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States",7151102,5,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0
CCN(CC)CC(=O)Nc1c(C)cccc1C,"INFERTILITY, FEMALE",_LIDOCAINE,NCT04518189,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Aswan University Hospital, Aswan, Egypt",5234957.0,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,RECURRENT MISCARRIAGE,_PREDNISOLONE,NCT03902912,Phase 3,Recruiting,Female,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Chinese University of Hong Kong, Hong Kong, Hong Kong",5178878,A61K9/0056,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,RECURRENT PREGNANCY LOSS,_HYDROXYCHLOROQUINE,NCT03305263,Phase 3,Recruiting,Female,18 Years to 39 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Rigshospitalet, København, Denmark",4181725,2,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
CC(=O)Nc1ccc(O)cc1,NEPHROLITHIASIS,_ACETAMINOPHEN,NCT03584373,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Jack D. Weiler Hospital, Bronx, New York, United States|Montefiore Hutchinson Campus, Bronx, New York, United States",5972916.0,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,NEPHROLITHIASIS,_OXYCODONE,NCT03584373,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Jack D. Weiler Hospital, Bronx, New York, United States|Montefiore Hutchinson Campus, Bronx, New York, United States",5508042,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,NEPHROLITHIASIS,_KETOROLAC,NCT03584373,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Jack D. Weiler Hospital, Bronx, New York, United States|Montefiore Hutchinson Campus, Bronx, New York, United States",5110493.0,A61K9/0048,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,END-STAGE KIDNEY DISEASE,_DEXTROSE,NCT02694068,,Recruiting,All,"20 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Other,"University of Washington, Seattle, Washington, United States",3964974,C12Q1/54,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0
O=C([O-])[O-].[Ca+2],CHRONIC KIDNEY DISEASES,_CALCIUM_CARBONATE,NCT04120922,Not Applicable,Recruiting,All,5 Years to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Great Ormond Street Hospital for Children, London, United Kingdom",5989588,A61K33/10,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
C=CCN.ClCC1CO1,CHRONIC KIDNEY DISEASES,_SEVELAMER,NCT04120922,Not Applicable,Recruiting,All,5 Years to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Great Ormond Street Hospital for Children, London, United Kingdom",5496545,7,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,18.0,22.012772336187602,6.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.68,149.619,12.53,1.0,0.0,1.0,8.38,20.06,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0
C=CC[NH3+].ClCC1CO1.O=C([O-])O,CHRONIC KIDNEY DISEASES,_SEVELAMER_CARBONATE,NCT04120922,Not Applicable,Recruiting,All,5 Years to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Great Ormond Street Hospital for Children, London, United Kingdom",,,1.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CN(C)C(=N)NC(=N)N,CHRONIC KIDNEY DISEASES,_METFORMIN,NCT03831464,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AZ Delta, Roeselare, West-Vlaanderen, Belgium|OLVZ Aalst, Aalst, Belgium|Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium|CHU Brugmann, Brussel, Belgium|UZ Brussel, Brussel, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Antwerp University Hospital, Edegem, Belgium|Ghent University Hospital, Ghent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|Centre Hospitalier Régional de la Citadelle, Liège, Belgium|Centre Hospitalier Universitaire Liège (CHU Liège), Liège, Belgium|Centre Hospitalier Régional de Namur, Namur, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|Centre Hospitalier de Wallonie Picarde, Tournai, Belgium|AZ Turnhout, Turnhout, Belgium",6288095.0,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CN(C)C(=N)N=C(N)N.Cl,CHRONIC KIDNEY DISEASES,_METFORMIN_HYDROCHLORIDE,NCT03831464,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AZ Delta, Roeselare, West-Vlaanderen, Belgium|OLVZ Aalst, Aalst, Belgium|Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium|CHU Brugmann, Brussel, Belgium|UZ Brussel, Brussel, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Antwerp University Hospital, Edegem, Belgium|Ghent University Hospital, Ghent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|Centre Hospitalier Régional de la Citadelle, Liège, Belgium|Centre Hospitalier Universitaire Liège (CHU Liège), Liège, Belgium|Centre Hospitalier Régional de Namur, Namur, Belgium|AZ Nikolaas, Sint-Niklaas, Belgium|Centre Hospitalier de Wallonie Picarde, Tournai, Belgium|AZ Turnhout, Turnhout, Belgium",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,OVARIAN HYPERSTIMULATION SYNDROME,_MONTELUKAST,NCT03794037,Phase 2,Recruiting,Female,20 Years to 37 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Banha University- Hawaa Fertility center, Banha, Qalyubiya, Egypt",8007830.0,A61K9/1623,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,NEPHROLITHIASIS,_CIPROFLOXACIN,NCT04374188,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Kafrelsheikh faculty of medicine, Kafr Ash Shaykh, Kafrelsheikh, Egypt",5286754,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,NEPHROLITHIASIS,_LEVOFLOXACIN,NCT04374188,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Kafrelsheikh faculty of medicine, Kafr Ash Shaykh, Kafrelsheikh, Egypt",5053407,C07D413/06,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0
CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,"INFERTILITY, FEMALE",_CLINDAMYCIN,NCT03363828,,Recruiting,All,18 Years to 40 Years   (Adult),Other,Observational Model: Cohort|Time Perspective: Prospective,"The Fertility Clinic Skive, Skive, Denmark|The Fertility Clinic, Regional Hospital of Skive, Skive, Denmark",5266329,A61M31/002,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,24.1811946857225,17.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.76,424.983,102.26,6.0,4.0,2.0,44.65,105.72,7.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,RENAL INSUFFICIENCY,_APIXABAN,NCT02664155,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CH ARRAS, Arras, Boulevard Georges Besnier, France|Chu Tours, Tours, Hôpital Trousseau, France|CH d'Agen-Nérac, Agen, France|Chu Amiens, Amiens 1, France|Chu Angers, Angers 9, France|CH Besançon, Besancon, France|CHU de Bordeaux, Bordeaux, France|CHU La Cavale Blanche Brest, Brest, France|HIA de Brest, Brest, France|CHU Castelnau-le-Lez, Castelnau Le Lez, France|CH Louis Pasteur - Chartres, Chartres, France|Chu Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|Hôpital La Tronche Grenoble, Grenoble 9, France|Hôpital Charles Foix - APHP Ivry sur Seine, Ivry sur Seine, France|Chu Limoges, Limoges, France|CHU Lyon, Lyon, France|HCL - Hôpital Edouard Herriot, Lyon, France|Chu Montpellier, Montpellier 5, France|CHU de Nantes - Hôpital Bellier, Nantes, France|CHU de Nantes - Hôpital Hôtel Dieu, Nantes, France|CHU Nice, Nice, France|HEGP - APHP Paris, Paris, France|Hôpital Louis Mourier- APHP Paris, Paris, France|CHU de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Chu Strasbourg, Strasbourg, France|CH Toulon, Toulon, France|HIA de Toulon, Toulon, France|CHU Toulouse, Toulouse 9, France|CH de Valenciennes, Valenciennes, France",6413980,C07D487/04,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,RENAL INSUFFICIENCY,_RIVAROXABAN,NCT02664155,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CH ARRAS, Arras, Boulevard Georges Besnier, France|Chu Tours, Tours, Hôpital Trousseau, France|CH d'Agen-Nérac, Agen, France|Chu Amiens, Amiens 1, France|Chu Angers, Angers 9, France|CH Besançon, Besancon, France|CHU de Bordeaux, Bordeaux, France|CHU La Cavale Blanche Brest, Brest, France|HIA de Brest, Brest, France|CHU Castelnau-le-Lez, Castelnau Le Lez, France|CH Louis Pasteur - Chartres, Chartres, France|Chu Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|Hôpital La Tronche Grenoble, Grenoble 9, France|Hôpital Charles Foix - APHP Ivry sur Seine, Ivry sur Seine, France|Chu Limoges, Limoges, France|CHU Lyon, Lyon, France|HCL - Hôpital Edouard Herriot, Lyon, France|Chu Montpellier, Montpellier 5, France|CHU de Nantes - Hôpital Bellier, Nantes, France|CHU de Nantes - Hôpital Hôtel Dieu, Nantes, France|CHU Nice, Nice, France|HEGP - APHP Paris, Paris, France|Hôpital Louis Mourier- APHP Paris, Paris, France|CHU de Rouen, Rouen, France|Chu Saint Etienne, Saint Etienne, France|Chu Strasbourg, Strasbourg, France|CH Toulon, Toulon, France|HIA de Toulon, Toulon, France|CHU Toulouse, Toulouse 9, France|CH de Valenciennes, Valenciennes, France",7157456,5,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
Cc1ccc(=O)n(-c2ccccc2)c1,RENAL INSUFFICIENCY,_PIRFENIDONE,NCT04126538,Phase 1,Recruiting,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Wuhan Union Hospital, Wuhan, Hubei, China",7988994,4,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,28.0,58.3174192488552,419.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,185.2218,20.31,1.0,0.0,2.0,20.28,57.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)C(C)C,"KIDNEY FAILURE, CHRONIC",_PROCALCITONIN,NCT03698877,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"The Rogosin Institute, New York, New York, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,CESAREAN SECTION COMPLICATIONS,_OXYTOCIN,NCT03777878,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Aswan University, Aswan, Egypt",3943246,A61K38/095,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,6.0,18.3658802028789,1710.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,CESAREAN SECTION COMPLICATIONS,_CARBETOCIN,NCT03777878,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Aswan University, Aswan, Egypt",5482931,A61K9/0043,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,30.357912893488496,49.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.14,988.1610000000001,362.51,12.0,10.0,3.0,101.0,250.18,18.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,ACUTE RENAL FAILURE,_IOHEXOL,NCT02961478,Phase 3,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University Hospital, Angers, France|Hospital center, Chartres, France|Hospital, Le Mans, France|University Hospital, Poitiers, France|University Hospital, Tours, France",4278654,A61K49/0452,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,RENAL DISEASE,_IOHEXOL,NCT03578523,,Recruiting,All,"18 Years to 95 Years   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Royal Derby Hospital, Derby, East Midlands, United Kingdom",4278654,A61K49/0452,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],CHRONIC KIDNEY DISEASES,_NIFEDIPINE,NCT03695107,,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Other|Time Perspective: Other,"The Third Xiangya Hospital of Central South University , , China,, Changsha, Hunan, China",5264446,A61K9/14,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,17.7416374052855,1857.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.49,346.3346,110.45,5.0,1.0,2.0,33.85,92.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],PRETERM PREMATURE RUPTURE OF MEMBRANE,_NIFEDIPINE,NCT03976063,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Trousseau University Hospital, Paris, France",5264446,A61K9/14,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,12.0,17.7416374052855,1857.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.49,346.3346,110.45,5.0,1.0,2.0,33.85,92.16,6.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,CHRONIC PROSTATITIS WITH CHRONIC PELVIC PAIN SYNDROME,_CETIRIZINE,NCT03167216,Early Phase 1,Recruiting,Male,"21 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Northwestern Medical Faculty Foundation, Chicago, Illinois, United States",6469009.0,1,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,CHRONIC PROSTATITIS WITH CHRONIC PELVIC PAIN SYNDROME,_CETIRIZINE_HYDROCHLORIDE,NCT03167216,Early Phase 1,Recruiting,Male,"21 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Northwestern Medical Faculty Foundation, Chicago, Illinois, United States",5993833,4,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,20.0,29.3394114868888,77.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,CHRONIC PROSTATITIS WITH CHRONIC PELVIC PAIN SYNDROME,_CROMOLYN,NCT03167216,Early Phase 1,Recruiting,Male,"21 Years to 80 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Northwestern Medical Faculty Foundation, Chicago, Illinois, United States",4145438,3,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,10.0,16.953120187272805,844.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.84,468.3665,165.89,11.0,3.0,4.0,44.38,114.11,8.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0
CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,PRETERM BIRTH,_DYDROGESTERONE,NCT03428685,Phase 2|Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Department of Obstetrics and Gynaecology, Hong Kong, Hong Kong, China",4014987.0,A61K9/0036,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,13.0,20.961416045504,368.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.27,312.4458,34.14,2.0,0.0,4.0,36.39,93.82,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,PRETERM PREMATURE RUPTURE OF MEMBRANE,_CHLORHEXIDINE,NCT04516226,Not Applicable,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albany Medical Center, Albany, New York, United States",5538353,A45D34/04,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,20.0,10.940676399926,1621.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.71,505.44699999999995,167.58,10.0,10.0,2.0,54.6,181.71,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1.O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,PRETERM PREMATURE RUPTURE OF MEMBRANE,_CHLORHEXIDINE_GLUCONATE,NCT04516226,Not Applicable,Recruiting,Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albany Medical Center, Albany, New York, United States",4199567,1,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,4.0,15.6389248239183,476.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,_RUCAPARIB,NCT04253262,Phase 1|Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Lifespan Cancer Institute, Providence, Rhode Island, United States",6495541,2,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0
CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1.Cl,URINARY RETENTION,_TAMSULOSIN_HYDROCHLORIDE,NCT03314025,Phase 2,Recruiting,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","St. Paul's Hospital, Vancouver, British Columbia, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|CHU de Quebec - Universite Laval, Quebec City, Quebec, Canada",6294711,C12N15/8286,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0,1.0,0.0,0.0,0.0,0.0,21.0,25.9225035421671,332.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0
CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1,"INFERTILITY, FEMALE",_ATOSIBAN,NCT03904745,Not Applicable,Recruiting,Female,18 Years to 40 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Bezmialem University, Istanbul, Turkey|Yeditepe University, Istanbul, Turkey",5482931,A61K9/0043,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,22.0,30.357912893488496,78.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.17,994.19,365.67,13.0,11.0,3.0,101.49,250.62,18.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1,PRETERM LABOR,_ATOSIBAN,NCT03369262,Phase 2,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Gynekologicko-porodnická klinika Fakultní nemocnice Brno, Brno, Czechia|Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze, Praha, Czechia|Ústav pro péči o matku a dítě, Praha, Czechia|Helsinki Universisty Hospital, Helsinki, Finland|Hilel Yafe Medical Center, Maternal Fetal Unit, Haifa, Israel|Rambam Medical Center, Maternal Fetal Unit, Haifa, Israel|Meir Medical Center, Obstetrics and Gynecology Department, Kfar Saba, Israel|Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women, Petah tikva, Israel|Moscow Regional Perinatal Center, Balašicha, Russian Federation|Kazan State Medical University, Kazan, Russian Federation|City clinical hospital № 15 named after O. M. Filatov of Healthcare Department of Moscow, Moscow, Russian Federation|Perinatal center of the City Clinical Hospital #24, Moscow, Russian Federation|Hospital La Paz, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Clínico Universitario de Santiago, Santiago De Compostela, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Hanoi Obstetrics and Gynecology Hospital, Hanoi, Vietnam|My Duc Hospital, Ho Chi Minh City, Vietnam",5482931,A61K9/0043,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,0.0,1.0,22.0,30.357912893488496,78.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.17,994.19,365.67,13.0,11.0,3.0,101.49,250.62,18.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0
CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,PRETERM BIRTH,_HYDROXYPROGESTERONE,NCT03292731,Phase 2|Phase 3,Recruiting,Female,18 Years to 45 Years   (Adult),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|University of Pittsburgh-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States",4014988,5,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,17.0,16.920265303188902,779.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.99,330.4611,54.37,3.0,1.0,4.0,37.9,94.11,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
O=C(Nc1ccc(C[C@@H]2CC[C@H]([C@H](O)c3ccccc3)N2)cc1)[C@@H]1CCc2nccc(=O)n21,OVERACTIVE BLADDER SYNDROME,_VIBEGRON,NCT03902080,Phase 3,Recruiting,Male,"45 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Private Practice, Huntsville, Alabama, United States|Coastal Clinical Research, Inc., Mobile, Alabama, United States|Alaska Urological Institute/AK Clinical Research Center, Anchorage, Alaska, United States|Gen1 Research- Arizona Urology Specialists, Glendale, Arizona, United States|Urological Associates Of Southern Arizona, Tucson, Arizona, United States|Incontinence Research Institute, Encinitas, California, United States|California Research Medical Group, Inc., Fullerton, California, United States|San Diego Clinical Trials, La Mesa, California, United States|Clinical Trials Research, Lincoln, California, United States|West Coast Urology, Los Alamitos, California, United States|American Institute of Research, Los Angeles, California, United States|Norris Healthcare Center 3, Los Angeles, California, United States|Tri Valley Urology Medical Group, Murrieta, California, United States|Northern California Research Corp, Sacramento, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Urology Specialists of Southern California (USSC), Sherman Oaks, California, United States|Skyline Urology, Torrance, California, United States|Urology Associates - Urology, Denver, Colorado, United States|Advanced Research for Health Improvement, Bonita Springs, Florida, United States|Imagine Research of Palm Beach County - Urology, Boynton Beach, Florida, United States|Tampa Bay Medical Research, Clearwater, Florida, United States|Private Practice, Orlando, Florida, United States|Pinellas Urology, Inc., Saint Petersburg, Florida, United States|Precision Clinical Research, Sunrise, Florida, United States|Clinical Research of Central Florida, Winter Haven, Florida, United States|Meridian Clinical Research - Urology, Savannah, Georgia, United States|Idaho Urologic Institute, Meridian, Idaho, United States|First Urology, Jeffersonville, Indiana, United States|The Iowa Clinic, West Des Moines, Iowa, United States|GU Research Network/Wichita Urology Group, Wichita, Kansas, United States|DelRicht Research, New Orleans, Louisiana, United States|Regional Urology, LLC, Shreveport, Louisiana, United States|Chesapeake Urology Research Associates, Baltimore, Maryland, United States|Boston Clinical Trials Inc - Urology, Boston, Massachusetts, United States|Mens Health Boston - Urology, Chestnut Hill, Massachusetts, United States|Bay State Clinical Trials, Inc., Watertown, Massachusetts, United States|Beaumont Hospital Royal Oak - Urology Research, Royal Oak, Michigan, United States|Michigan Intitute of Urology - Urology, Troy, Michigan, United States|CentraCare Clinic - Adult & Pediatric Urology, Sartell, Minnesota, United States|Poplar Bluff Urology, Poplar Bluff, Missouri, United States|Adult & Pediatric Urology P.C. - Urology, Omaha, Nebraska, United States|Excel Clinical Research - Internal Medicine, Las Vegas, Nevada, United States|Private Practice, Las Vegas, Nevada, United States|Premier Urology Group, LLC, Edison, New Jersey, United States|New Jersey Urology NJU, Englewood, New Jersey, United States|New Jersey Urology, LLC, Mount Laurel, New Jersey, United States|New Jersey Urology, LLC, Voorhees, New Jersey, United States|Urology Group Of New Mexico, Albuquerque, New Mexico, United States|Albany Medical College, Albany, New York, United States|Brooklyn Urology Research Group, Brooklyn, New York, United States|Urological Surgeons of Long Island, Garden City, New York, United States|Manhattan Research Associates, New York, New York, United States|Columbia University Medical Center - Clinical Research, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Advanced Urology Centers of NY, A Division of Integrated Medical Professionals (IMP), Plainview, New York, United States|Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States|Duke Medical Center - Urology, Durham, North Carolina, United States|Carolina Institute for Clinical Research, Fayetteville, North Carolina, United States|Alliance Urology Specialists - Greensboro, Greensboro, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Associated Urologists of North Carolina - Urology, Raleigh, North Carolina, United States|Clinical Research Solutions, Middleburg Heights, Ohio, United States|Lowcountry Urology, North Charleston, South Carolina, United States|Urology Clinics of North Texas, Dallas, Texas, United States|Advances In Health, Inc., Houston, Texas, United States|Urology San Antonio, San Antonio, Texas, United States|Baylor Scott & White Medical Center, Temple, Texas, United States|Wasatch Clinical Research LLC, Salt Lake City, Utah, United States|Urology of Virginia (UVA), Virginia Beach, Virginia, United States|Seattle Urology Research Center, Burien, Washington, United States|Uz Antwerpen, Edegem, Antwerpen, Belgium|Algemeen Stedelijk Ziekenhuis, Aalst, Oost-Vlaanderen, Belgium|AZ Maria Middelares - Campus Maria Middelares, Gent, Oost-Vlaanderen, Belgium|UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant, Belgium|AZ Delta - Campus Wilgenstraat, Roeselare, West-Vlaanderen, Belgium|CHU de Liège - Domaine Universitaire du Sart Tilman - Urologie, Liège, Belgium|Private Practice, Brampton, Ontario, Canada|Bluewater Clinical Research Group Inc, Sarnia, Ontario, Canada|Sunnybrook Health Sciences Center, Toronto, Ontario, Canada|Diex Research Quebec Inc., Quebec City, Quebec, Canada|Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada|Diex Research Victoriaville Inc., Victoriaville, Quebec, Canada|University of Szeged, Szeged, Csongrád, Hungary|DRC Kft., Sopron, Gyor-Moson-Sopron, Hungary|Szent Borbala Korhaz, Tatabanya, Komárom-Esztergom, Hungary|Semmelweis Egyetem, Budapest, Hungary|Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet, Budapest, Hungary|Szarka Ödön Egyesitett Egeszsegügyi es Szocialis Intezmeny, Csongrad, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór, Nyiregyhaza, Hungary|Uro-Clin Kft., Pècs, Hungary|JSC Saules seimos medicinos centras, Kaunas, Kauno Apskritis, Lithuania|Uab ""Vakk"", Kaunas, Kauno Apskritis, Lithuania|Hospital of University of Health Sciences Kauno Klinikos, Kaunas, Kauno Apskritis, Lithuania|Respublikine Klaipedos ligonine - Urology, Klaipeda, Klaipedos Apskritis, Lithuania|Klaipedos Universitetine Ligonine (Klaipeda Hospital), Klaipeda, Klaipedos Apskritis, Lithuania|National Cancer Institute, Vilnius, Vilniaus Apskritis, Lithuania|Republican Vilnius University Hospital, Vilnius, Vilniaus Apskritis, Lithuania|Vilnius University Hospital Santariskiu Klinikos, Vilnius, Vilniaus Apskritis, Lithuania|Vilnius City Clinical Hospital, Vilnius, Vilniaus Apskritis, Lithuania|Wojewodzki Szpital Specjalist, Wroclaw, Dolnoslaskie, Poland|EuroMediCare Szpital Specjalistyczny z Przychodnia, Wroclaw, Dolnośląskie Województwo, Poland|Nasz Lekarz Osrodek Badan Klinicznych, Bydgoszcz, Kujawsko-pomorskie, Poland|NZOZ Specjalista, Kutno, Lódzkie, Poland|ETG Lodz, Lodz, Lódzkie, Poland|Centrum Medyczne PROMED, Krakow, Małopolskie Województwo, Poland|Prywatny Gabinet Urologiczny dr n. med. Maciej Szwedowski, Opole, Opolskie, Poland|Szpital Specjalistyczny Slupsk, Slupsk, Pomorskie, Poland|Centrum Urologiczne sp. z o.o., Myslowice, Silesia, Poland|Clinical Research Center Sp. z o.o., Medic-R Sp. K., Poznan, Wielkopolskie, Poland|Nzoz Heureka, Piaseczno, Poland|Hospital Garcia de Orta, Almada, Setúbal, Portugal|Centro Clínico Académico Braga, Hospital de Braga, Braga, Portugal|Hospital Senhora de Oliveiro Guimaraes EPE, Guimaraes, Portugal|H. Egas Moniz. Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal|H. Santo António. Centro Hospitalar do Porto, Porto, Portugal|Hospital General Universitario Gregorio Marañón, Majadahonda, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain|Hospital del Mar, Barcelona, Spain|Clínica Universitaria de Navarra, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|H.U. Virgen de la Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain",,,0.0,0.0,1.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,2.2,444.535,94.03,5.0,3.0,5.0,48.41,126.71,6.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
O=C(O)[C@H]1C2CCC(CC2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(F)cc23)ncc1F,"KIDNEY FAILURE, CHRONIC",_PIMODIVIR,NCT03947814,Phase 1,Recruiting,All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"CRS Clinical Research Services Kiel GmbH, Kiel, Germany|APEX GmbH, Munchen, Germany",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,3.07,399.402,103.79,6.0,3.0,5.0,38.46,112.27,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,HEMODIALYSIS ACCESS FAILURE,_PACLITAXEL,NCT04285073,Not Applicable,Recruiting,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Samsung Medical Center, Seoul, Korea, Republic of",5439686,A61K47/6925,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0
CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC,CESAREAN SECTION COMPLICATIONS,_MISOPROSTOL,NCT03774706,Not Applicable,Recruiting,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Aswan University, Aswan, Egypt",5601843,5,0.0,1.0,0.0,0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,30.8507361547465,370.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.88,382.5341,83.83,4.0,2.0,1.0,45.38,107.88,14.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0
O=C[C@H](O)[C@H](O)[C@H](O)CO,PROSTATE CANCER,_RIBOSE,NCT03334500,Early Phase 1,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,-2.3,150.1299,97.99,5.0,4.0,0.0,13.39,31.38,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0
O=P1(N(CCCl)CCCl)NCCCO1,CANCER,_CYCLOPHOSPHAMIDE,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",3987166,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,CANCER,_SIROLIMUS,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",5212155,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,1.0,0.0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,CANCER,_ETOPOSIDE,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",4701327,7,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,CANCER,_CELECOXIB,NCT02574728,Phase 2,Recruiting,All,"12 Months to 30 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Nemour's Children's Specialty Care Jacksonville, Jacksonville, Florida, United States|Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States|Children's Healthcare of Atlanta, Scottish Rite, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Virginia Health System, Charlottesville, Virginia, United States",5972986.0,4,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,CANCER,_GEMCITABINE,NCT03507491,Phase 1,Recruiting,All,"6 Months to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Chilldren's Healthcare of Atlanta, Atlanta, Georgia, United States|Children's Mercy Hospital, Kansas City, Missouri, United States",4808614.0,C07D317/30,1.0,0.0,0.0,0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0,0.0,0.0,1.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0
COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O,COUGH,_GEFAPIXANT,NCT04193176,Phase 3,Recruiting,Female,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Center for Clinical Trials, LLC ( Site 0021), Paramount, California, United States|Health Awareness, Inc. ( Site 0038), Jupiter, Florida, United States|Well Pharma Medical Research, Corp. ( Site 0040), Miami, Florida, United States|Lenus Research & Medical Group Llc ( Site 0007), Sweetwater, Florida, United States|Florida Pulmonary Research Institute, LLC ( Site 0008), Winter Park, Florida, United States|Paul A. Shapero, MD ( Site 0037), Bangor, Maine, United States|Chesapeake Clinical Research, Inc ( Site 0022), White Marsh, Maryland, United States|University of Missouri ENT & Allergy Center ( Site 0010), Columbia, Missouri, United States|Alliance for Multispecialty Reseach, LLC ( Site 0035), Las Vegas, Nevada, United States|Albuquerque Clinical Trials ( Site 0019), Albuquerque, New Mexico, United States|American Health Research ( Site 0027), Charlotte, North Carolina, United States|Clinical Research of Gastonia ( Site 0016), Gastonia, North Carolina, United States|PMG Research of Wilmington ( Site 0004), Wilmington, North Carolina, United States|Temple University ( Site 0003), Philadelphia, Pennsylvania, United States|AAPRI Clinical Research Institute ( Site 0031), Warwick, Rhode Island, United States|Diagnostics Research Group ( Site 0013), San Antonio, Texas, United States|TPMG Clinical Research ( Site 0025), Newport News, Virginia, United States|Tidewater Physician Multispecialty Group, PC ( Site 0028), Williamsburg, Virginia, United States|Bellingham Asthma & Allergy ( Site 0006), Bellingham, Washington, United States|Centro Medico Dra De Salvo ( Site 0300), Buenos Aires, Argentina|Investigaciones en Patologias Respiratorias ( Site 0302), Tucuman, Argentina|Fundacion Centro de Investigacion Clinica CIC ( Site 0401), Medellin, Antioquia, Colombia|Universidad Pontificia Bolivariana - Clinica Universitaria Bolivariana ( Site 0408), Medellin, Antioquia, Colombia|Medplus Medicina Prepagada ( Site 0402), Bogota, Distrito Capital De Bogota, Colombia|Praxis Dr. Wehgartner-Winkler ( Site 0906), Augsburg, Bayern, Germany|Zentrum fuer ambulante pneumologische Forschung Marburg GbR ( Site 0900), Marburg, Hessen, Germany|Ballenberger Freytag Wenisch Institut fuer klinische Forschung GmbH ( Site 0905), Neu-Isenburg, Hessen, Germany|Pneumologicum im Suedstadtforum ( Site 0908), Hannover, Niedersachsen, Germany|Bethel Soluciones Medicas S.A. ( Site 0506), Guatemala, Guatemala|Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0500), Guatemala, Guatemala|Clinica Medica Especializada en Neumologia y Tisiologia ( Site 0504), Guatemala, Guatemala|Clinica Medica Especializada en Neumologia ( Site 0502), Guatemala, Guatemala|Private Clinic ( Site 0505), Guatemala, Guatemala|Clinica Privada Dr. Jose Francisco Flores Lopez ( Site 0503), Guatemala, Guatemala|Kaplan Medical Center ( Site 1103), Rehovot, HaMerkaz, Israel|Chaim Sheba Medical Center ( Site 1101), Ramat Gan, Tel Aviv, Israel|Sourasky Medical Center ( Site 1100), Tel-Aviv, Tell Abib, Israel|Shaare Zedek Medical Center ( Site 1107), Jerusalem, Yerushalayim, Israel|Hadassah Ein Karem Jerusalem ( Site 1108), Jerusalem, Yerushalayim, Israel|Rabin Medical Center ( Site 1102), Petah Tikva, Israel|Carmel Medical Center ( Site 1104), Haifa, Ḥeifā, Israel|Chonbuk National University Hospital ( Site 1507), Jeonju-si, Jeonrabugdo, Korea, Republic of|Wonju Severance Christian Hospital ( Site 1502), Wonju-si, Kang-won-do, Korea, Republic of|The Catholic University of Korea Eunpyeong St Mary s Hospital ( Site 1506), Seoul, Korea, Republic of|Konkuk University Medical Center ( Site 1504), Seoul, Korea, Republic of|Asan Medical Center ( Site 1505), Seoul, Korea, Republic of|Clinica Ricardo Palma ( Site 0601), San Isidro, Lima, Peru|Asociacion Civil por la Salud ( Site 0602), Lima, Peru|Hospital Nacional Arzobispo Loayza ( Site 0607), Lima, Peru|Clinica Belen ( Site 0604), Piura, Peru|RSBHI Belgorod regional clinical hospital of Prelate Ioasafa ( Site 1416), Belgorod, Belgorodskaya Oblast, Russian Federation|GBUZ Regional Clinical Hospital 3 ( Site 1420), Chelyabinsk, Chelyabinskaya Oblast, Russian Federation|City Clinical Hospital No. 3 them. M. A. Podgorbunskogo ( Site 1400), Kemerovo, Kemerovskaya Oblast, Russian Federation|Clinic of FSBEI HE OmSMU of Minzdrav ( Site 1438), Omsk, Omskaya Oblast, Russian Federation|Perm Clinical Center of the Federal Medical and Biological Agency ( Site 1450), Perm, Permskiy Kray, Russian Federation|SEIHPE Saint Petersburg SMU ( Site 1434), Saint Petersburg, Sankt-Peterburg, Russian Federation|Limited Liability Company Kurator ( Site 1424), St. Petersburg, Sankt-Peterburg, Russian Federation|Saratov City Clinical Hospital 2 n.a. V.I. Razumovsky ( Site 1452), Saratov, Saratovskaya Oblast, Russian Federation|State health Agency Ulyanovsk regional clinical hospital ( Site 1414), Ulyanovsk, Ul Yanovskaya Oblast, Russian Federation|Voronezh Regional Clinical Hospital #1 ( Site 1440), Voronezh, Voronezskaja Oblast, Russian Federation|SBCIH of the Yaroslavl region Central city hospital ( Site 1428), Yaroslavl, Yaroslavskaya Oblast, Russian Federation|Hospital Clinico Universitario de Santiago ( Site 1805), Santiago de Compostela, La Coruna, Spain|Hospital General Universitario Gregorio Maranon ( Site 1808), Madrid, Madrid, Comunidad De, Spain|SE Road Clinical Hospital 2 of Kyiv station ( Site 2812), Kyiv, Kyivska Oblast, Ukraine|F.G.Yanovskyy Institute of Phthisiology and Pulmonology ( Site 2808), Kyiv, Kyivska Oblast, Ukraine|F.G.Yanovskyy Institute of Phthisiology and Pulmonology ( Site 2819), Kyiv, Kyivska Oblast, Ukraine|Odesa regional clinical hospital ( Site 2804), Odesa, Odeska Oblast, Ukraine|City Polyclinic N20 ( Site 2806), Odesa, Odeska Oblast, Ukraine|Poltava City Clinical Hospital -1 ( Site 2813), Poltava, Poltavska Oblast, Ukraine|Private Small-Scale Enterprise Medical Centre ""Pulse"" ( Site 2809), Vinnytsya, Vinnytska Oblast, Ukraine|Volyn Regional Clinical Hospital ( Site 2816), Lutsk, Volynska Oblast, Ukraine|Medical Center of LLC Medical Clinic Blahomed ( Site 2815), Kyiv, Ukraine|Medinova North London Dedicated Research Centre ( Site 2705), Northwood, England, United Kingdom|GP Direct ( Site 2714), Harrow, London, City Of, United Kingdom|Medinova Lakeside Dedicated Research Centre ( Site 2712), Corby, Northamptonshire, United Kingdom|West Walk Surgery ( Site 2700), Yate, South Gloucestershire, United Kingdom|Kings College Hospital NHS Foundation Trust ( Site 2702), London, Southwark, United Kingdom|Medinova Warwickshire Dedicated Research Centre ( Site 2715), Kenilworth, Warwickshire, United Kingdom",7858632,5,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0,0.0,1.0,0.0,0.0,0.0,30.0,69.8494835622907,7.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.87,353.4,156.44,7.0,3.0,2.0,34.62,91.44,5.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,1.0,1.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,1.0,0.0,0.0,1.0
NCC(=O)CCC(=O)O,GENITAL WARTS,_AMINOLEVULINIC_ACID,NCT03948321,Not Applicable,Recruiting,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Shanghai Dermatology Hospital, Shanghai, Shanghai, Jingan, China, China",5422093,1,1.0,0.0,0.0,0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0,1.0,0.0,0.0,0.0,0.0,21.0,23.261257931374306,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,131.1299,80.39,4.0,2.0,0.0,12.55,30.45,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0
